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1 
1 Introduction 
1.1 Nature of Gram-negative bacterial infections 
Most microorganisms do not cause disease, but those capable of provoking disease in 
nearly any susceptible host, are truly considered pathogens (NCBI, 2007). Thus, clinical 
microbiologists have long recognised the relevance of identifying infectious microbial 
pathogens, since they are generally responsible for inducing diseases in humans 
(Fournier et al., 2013).  
In the last decades, non-fermenting Gram-negative (NFGN) bacteria have emerged as 
important opportunistic pathogens, despite efforts made to optimize the surveillance and 
treatment of infectious diseases (Enoch et al., 2007). This particular group of bacteria is 
found widespread in the environment (soil and water) and primarily affects critically ill or 
immunocompromised patients (Enoch et al., 2007; McGowan Jr, 2006). Indeed, they 
represent a challenge for health care due to their propensity for multiple, intrinsic or 
acquired drug resistance; features that characterise them as multiple-drug resistant 
(MDR) organisms (MDROs) (Bhattacharya, 2013). As a consequence, MDROs have 
great impact on morbidity and mortality rates in patients (Slama, 2008). 
For a long time Pseudomonas aeruginosa has played a dominant role as a pathogen 
among the non-fermenting Gram-negative pathogens, as it is often the cause of 
respiratory infections in patients, especially those suffering from chronic lung diseases 
and cystic fibrosis (CF) (Hogardt and Heesemann, 2010). However, this predominantly 
P. aeruginosa-centred view has been altered by the ever-growing role of Stenotropho-
monas maltophilia, a global emerging Gram-negative bacteria mostly associated with 
human infections, especially those of the respiratory tract (Brooke, 2012; de Vrankrijker 
et al., 2010; Barchitta et al., 2009).  
 
1.2 History and clinical significance of S. maltophilia 
In the early 1940s, Stenotrophomonas maltophilia was initially described as Bacterium 
booker and later named Pseudomonas maltophilia (Hugh and Leifson, 1963). However, 
subsequent allocation of this species to the genus Xanthomonas was supported by 
results obtained from rRNA (ribosomal ribonucleic acid) cistron analysis (Swings et al., 
1983). A large study involving Xanthomonas strains, which analysed 295 phenotypic 
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features, revealed the identity of seven strains as X. maltophilia, although two of them 
were type strains Pseudomonas betle and Pseudomonas hibiscicola (Van den Mooter 
and Swings, 1990). Due to intense debates regarding the transfer of P. maltophilia to the 
genus Xanthomonas, the creation of a genetic genus which would include only a single 
species was proposed and accepted, Stenotrophomonas maltophilia (Palleroni and 
Bradbury, 1993). Stenotrophomonas’ (Gr. adj. stenus = narrow, Gr. n. trophus = one 
who feeds, Gr.n. monas= unit) designation would then reflect the observed characteristic 
of its limited spectrum of nutrition (Stanier et al., 1966). Data based on DNA 
(deoxyribonucleic acid)-rRNA hybridization studies, sequencing and mapping 
investigations of PCR (polymerase chain reaction)-amplified 16S rRNA genes, 
eventually resulted in a consensus classification of X. maltophilia as S. maltophilia 
(Denton and Kerr, 1998; Nesme et al., 1995).  
S. maltophilia is usually considered as a pathogen with reduced virulence, but it can 
cause a broad spectrum of nosocomial infection complications with a considerable 
mortality rate of up to 37.5 % (Falagas et al., 2009). The most common clinical 
manifestations caused by this bacterium include respiratory tract infections (Nicodemo 
and Paez, 2007; Weber et al., 2007; Nseir et al., 2006); bacteraemia (Chang et al., 
2012; Lai et al., 2004), biliary sepsis (Papadakis et al., 1995); infections of the bones 
and joints (Bin Abdulhak et al., 2009; Landrum et al., 2005), urinary tract (Vartivarian et 
al., 1996)  and soft tissues (Sakhnini et al., 2002); eye infections (Penland and 
Wilhelmus, 1996); endocarditis (Wladis, 2011; Takigawa et al., 2008) and meningitis 
(Rojas et al., 2009).  
Respiratory tract infections are often a clinical sign observed as consequence of 
stenotrophomonad infection (Brooke, 2012). Since it is quite difficult to distinguish 
between a simple colonisation and infection caused by this pathogen, diagnosis should 
be based on the association of physical examination, medical record and diverse clinical 
tests (results from radiograph, laboratory tests, image findings and microbiology assays) 
(Nicodemo and Paez, 2007). Since most of these findings are frequently associated with 
polymicrobial infections and the role played by individual species is still not clearly 
defined, such described clinical situations can be even more complex. However, there 
are no doubts that S. maltophilia is able to cause nosocomial pneumonia as shown in 
previous investigations (Nseir et al., 2006; Weber et al., 2007). A four-year study 
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examined the prevalence, risk factors and effect on outcome of MDR bacteria in patients 
diagnosed with severe acute exacerbation of chronic obstructive pulmonary disease 
(COPD). It was shown that COPD patients with severe acute exacerbation were 
commonly infected with MDRO’s, and S. maltophilia was isolated from 3.0 % of this 
cohort. Further, it has been demonstrated that this pathogen accounts for 6.75 % and 
1.11 % of the cases of ventilator-associated pneumonia and hospital-acquired 
pneumonia, respectively (Weber et al., 2007). It is important to remember that the 
mortality rate as a consequence of S. maltophilia pulmonary infections is high, especially 
when there are complications such as bacteraemia and airway obstruction (Nicodemo 
and Paez, 2007; Fujita et al., 1996). 
Bloodstream infections represent a serious threat to the patient’s health (Vidal et al., 
2003) and indwelling medical devices, such as central venous catheters (CVC), are 
common sources of NFGN bacteraemia (Hanna et al., 2004). S. maltophilia is a 
flagellated and fimbriated bacterium. These external appendages enable the bacteria to 
efficiently adhere to a variety of surfaces, both biotic and abiotic (Pompilio et al., 2010b). 
As a consequence of this, S. maltophilia readily forms biofilms on medical devices, 
resulting in eventual patient infection (Yeshurun et al., 2010; Lai et al., 2006). A 
retrospective cohort study carried out at the Chaim Sheba Medical Center in Israel 
examined 570 adult patients that underwent hematopoietic stem cell transplantation 
(HSCT) (Yeshurun et al., 2010). Through this four-year investigation, results showed 
that 19 (3.3 %) of the HSCT patients had S. maltophilia isolated from their blood 
cultures. During the time of infection, 17 (90.0 %) of these patients had CVC, from which 
15 (88.0 %) of them were bacteraemic and the remaining two (12.0 %) showed signs of 
other invasive infections. Another study has observed that haematological and 
oncological patients were also susceptible to CVC-related S. maltophilia systemic 
infections and recurrent bacteraemia (Lai et al., 2006). The major clinical characteristics 
observed in these patients were nosocomial bacteraemia, preceding antibiotic therapy 
and neutropenia. Univariate analysis characterised long-lasting (> 10 days) neutropenia 
and initial failure to remove the CVC as risk factors. Relapse cases were, in fact, not 
reinfection episodes, as the same strain was identified through random amplified 
polymorphic (RAPD) DNA. Therefore, it has been strongly suggested that CVC removal 
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is crucial for successful treatment of CVC-related S. maltophilia bacteraemia as well as 
for prevention of relapses.  
Akin to respiratory infection, differentiation between colonisation and infection in the 
urinary tract due to S. maltophilia can also be challenging (Falagas et al., 2009; 
Vartivarian et al., 1996). Long-term urinary bladder catheterisation, urinary tract 
abnormalities and genitourinary malignancies are usually associated with this type of 
infection. There is an increased risk of developing severe infection in 
immunocompromised patients, especially if the therapy involves antibiotics ineffective 
against this pathogen (Vartivarian et al., 1996).  
Infection syndromes of intact skin and soft tissues are frequent and predominantly affect 
immunocompromised hosts suffering from haematologic malignancies, neutropenia, 
undergoing chemotherapy, use of CVC or exposed to broad-spectrum antibiotic therapy 
(including carbapenems) (Bin Abdulhak et al., 2009).  If the S. maltophilia skin infections 
are properly identified and treated, the outcomes can be favourable. Several reports 
have also described S. maltophilia endocarditis. Most cases were related to intravenous 
drug abusers or complications relating to prosthetic valve implantation surgery (Rojas et 
al., 2009; Khan and Mehta, 2002; Denton and Kerr, 1998). 
Rare infections due to S. maltophlia include bone and eye infections, as well as 
meningitis. In a case report, a month after a discectomy procedure, osteomyelitis was 
described and successful treatment was achieved through administration of a dual 
therapy, consisting of use of trimethoprim-sulfamethoxazole with another antimicrobial 
agent to which the isolate was susceptible in vitro (Landrum et al., 2005). Further, a 
retrospective review of laboratorial records showed that corneal transplantation, 
hospital-acquired postkeratoplasty, soft contact lens wear, herpes simplex virus keratitis, 
Stevens-Johnson syndrome, and toxic epidermal necrolysis were predisposing factors 
for an eye infection (conjunctivitis, keratitis, and endophthalmitis) (Penland and 
Wilhelmus, 1996). Meningitis has only been reported in 15 cases, which seem to be 
strongly related to neurosurgical procedures (Yemisen et al., 2008).  
Conversely, S. maltophilia is not exclusively associated with nosocomial infections. A 
systematic review indicated several reports dealing with community-acquired infections 
(determined as infections that occur between 48 h and 72 h prior to hospitalisation) in 
children and adult patients who, in most cases, possessed some type of comorbidity 
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(COPD, trauma, CVC, prior antibiotic use, malignancy, prior hospitalisation, human 
immunodeficiency virus (HIV) infection, or other immune suppression) (Falagas et al., 
2009). Similarly to nosocomial infections, common symptoms observed in these patients 
were: bacteraemia; ocular, respiratory tract and wound/tissue infections; otitis and 
cellulitis.   
Interestingly, it has been suggested that S. maltophilia is associated with polymicrobial 
infections (Davies and Rubin, 2007). Recently, a six-year study conducted in a university 
hospital in Greece analysed data from 68 non-CF patients. Indeed, it was observed that 
33.8 % of S. maltophilia infections were associated with polymicrobial infections 
(Samonis et al., 2012). Whether other more virulent pathogens may play a more pivotal 
role than S. maltophilia remains unclear, but there is evidence linking poor prognosis 
with polymicrobial infections (Araoka et al., 2010). 
   
1.3 Microbiology 
S. maltophilia consist of straight or slightly curved non-sporulating Gram-negative, rod-
shaped cells, which are 0.5 to 1.5µm long (Hugh and Ryschenkow, 1961) (Figure 1). 
They can be found as single cells or in pairs and are motile due to the presence of a few 
polar flagella (Palleroni and Bradbury, 1993). It can also form small-colony variants, 
considered an adapted survival form in chronic infections, which can be difficult to detect 
in clinical specimens (Anderson et al., 2007). When inoculated in Columbia blood agar, 
it forms small greyish, slightly mucous colonies on blood agar. However, some strains 
may cause a brownish discolouration in clear media, most likely due to secondary 
chemical reactions among extracellular products. This microorganism lives strictly 
aerobically and its optimal growth temperature varies between 30-35 °C (Denton and 
Kerr, 1998).  
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Figure 1 Stenotrophomonas maltophilia. A) Stenotrophomonas maltophilia culture on Columbia blood 
agar incubated at 35 °C for a period of 24 h. B) Gram-staining of S. maltophilia.   
 
Although, standard microbiological data refer to S. maltophilia as an oxidase-negative 
bacterium, recent data analysis of a collection of 766 isolates indicated that 
approximately 20.0 % of these strains were actually oxidase positive (Carmody et al., 
2011).  
Misidentification of S. maltophilia could have major clinical implications. For example, a 
study observed that 3 (9.0 %) out of 32 clinical isolates obtained from CF patients were 
incorrectly identified as Burkholderia cepacia, due to delayed analysis of oxidase test 
results (Burdge et al., 1995). In this particular case, as B. cepacia is a significant 
pathogen in CF patients (CFFPR, 2012), misinterpretation of test results raises 
particular concern. Further, a recent study observed that API-20NE, a method typically 
used for the identification of clinical isolates, has only correctly identified 3.0 % of S. 
maltophilia isolates, recognising most of them as either B. cepacia or Pseudomonas 
luteola (Pinot et al., 2011). 
Identification can also be challenging and complex because S. maltophilia can be 
coisolated with other microorganisms, such as bacteria or yeast (e.g. P. aeruginosa, 
Staphylococcus aureus, Acinetobacter baumanii, Escherichia coli, Enterobacter species, 
Candida albicans) in samples recovered from patients (Araoka et al., 2010; Gülmez and 
Hasçelik, 2005; Lai et al., 2004). Thus, to improve the isolation of this pathogen from 
1 Introduction 
 
 
7 
polymicrobial cultures or environmental specimens, a number of selective media have 
been designed (Denton et al., 2000; Kerr et al., 1996; Juhnke and des Jardin, 1989). 
Despite this, there is currently no selective medium approved by international guidelines, 
nor is such a medium commercially available.   
 
1.4 Pathogenicity 
1.4.1 Extracellular enzymes 
Several factors may contribute to S. maltophilia colonisation or infection of hosts, such 
as production of proteinase, lipase, and elastase. It is believed that the primary function 
of proteinases is to provide a source of free amino acids or simple sugars for bacterial 
survival and growth (Travis et al., 1995). However, bacterial proteinases during an 
infection are also virtually unregulated by the host proteinase inhibitors, and therefore, 
are capable of destroying host proteins (Windhorst et al., 2002). For example, the 
extracellular protease StmPr1 from S. maltophilia degrades several human proteins from 
serum (fibronectin and fibrinogen) and connective tissue (collagen), contributing to local 
tissue damage and hemorrhage (Windhorst et al., 2002).   
 
1.4.2 Lipopolysaccharide 
Lipopolysaccharide (LPS) is a major component of the outer membrane of most Gram-
negative bacteria (Wang and Quinn, 2010). The LPS comprises three structure 
components: O-antigen repeats, core polysaccharides, and lipid A, the last being 
responsible for the toxic effects experienced during infections caused by Gram-negative 
bacteria (Wang and Quinn, 2010). Early reports have described the contribution of LPS 
regarding its role in the development and maintenance of colonies (DeShazer et al., 
1998; Goldberg et al., 1995; Rahmati-Bahram et al., 1996). A loss of O-polysaccharide 
production in mutant P. aeruginosa will produce avirulent isolates (Goldberg et al., 
1995). In S. maltophilia, the phosphoglucomutase (spgM) gene encodes an enzyme for 
the biosynthesis of phosphoglucomutase, which is correlated to LPS synthesis. 
Consequently, spgM mutants exhibit a modest increase in susceptibility to diverse 
antimicrobials and proved to be completely avirulent in infection experiments performed 
with animal host models. Therefore the outer membrane polysaccharide is a virulence 
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factor involved not only in colonisation, but also resistance to complement mediated cell 
killing.  
 
1.4.3. Immunostimulatory effects 
Another feature that supports the development of infectious manifestations is the 
immunostimulant effect of S. maltophilia, especially upon interleukin- 8 (IL-8) and tumor 
necrosis factor alpha expression (TNFα) (Waters et al., 2007; Vickers and Smikle, 
2006). IL-8 and TNFα are defined as anti-inflammatory cytokines that activate 
neutrophils and macrophages (Opal and DePalo, 2000). Lipid A stimulation in 
peripheral-blood monocytes and alveolar macrophages induces the production of TNFα, 
which is in part responsible for the pathogenesis of airway inflammation (Waters et al., 
2007; Vickers and Smikle, 2006). S. maltophilia substantially induces IL-8 expression 
and recruitment of polymorphonuclear leukocytes into the lungs (Waters et al., 2007). A 
prolonged exposure to these cytokines might disrupt pulmonary functions, and 
developed into pneumonia-like conditions (Miller et al., 2005).  
 
1.4.4. Adherence and biofilms 
An essential step for a successful colonisation, and ultimately, induction of disease, 
resides in the ability of pathogens to adhere to host surfaces (Finlay and Falkow, 1997). 
This phenomenon is usually mediated by fibrillar structures known as fimbrae or pili 
(Klemm and Schembri, 2000). It is believed that bacterial colonisation will be favoured 
either through direct binding of the bacteria to the host target cell mediated by fimbrae or 
pili or through indirect pilus cross-linking among bacteria (De Oliveira-Garcia et al., 
2003; Finlay and Falkow, 1997). A positively charged surface and flagella, together with 
production of fimbrial adhesions, have been associated with biofilm formation. A 
bacterial biofilm consists of a microbial community embedded in an extra-cellular 
polysaccharide matrix or extracellular polymeric substances (EPS) (Flemming and 
Wingender, 2010). EPS are composed by polysaccharides (Ma et al., 2009; Zogaj et al., 
2001), extracellular DNA (Mann et al., 2009; Rice et al., 2007) and other 
macromolecules, as well as biosurfactants (Pamp and Tolker-Nielsen, 2007; Davey et 
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al., 2003), flagella and pili (Harmsen et al., 2010), lipids (Matsuyama et al., 1990) and 
proteins (Borlee et al., 2010; Fexby et al., 2007).  
S. maltophilia is recognized by its ability to form biofilms on abiotic surfaces including 
glass and plastics like polystyrene (Brooke, 2012), as well as on host tissues such as 
bronchial epithelial cells (Pompilio et al., 2010b) (Figure 2). 
1 Introduction 
 
 
10 
 
Figure 2 Bacterial biofilm formation. A) The pathways of bacterial biofilm development; surface-attached (right) and non- surface attached (left) 
(modified from Bjarnsholt et al., 2013). B) Scanning electron microscope (SEM) observation of 24 h-old-biofilm formed by clinical isolate 
S. maltophilia OBGTC9 on IB3-1 bronchial epithelia cell monolayer (Reprint from Pompilio et al., 2010b with permission from the corresponding 
author).  
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In vitro tissue culture assays have demonstrated that adherence to epithelial cells (HEp-
2 monolayer cells) and also to inner surfaces was linked to a specific protein, the 
S. maltophilia frimbriae 1 (SMF-1) (De Oliveira-Garcia et al., 2003). In the presence of 
anti-SMF-1 antibodies, the adherence of this microbial pathogen to eukaryotic cells was 
inhibited. Interestingly, inhibition of adherence and biofilm formation occurred in an anti-
SMF-1 dose-dependent manner, suggesting that fimbriae assist in interactions between 
the S. maltophilia cell surface and host cell/abiotic surfaces. 
Bacterial cells are not physically aware of the density of other microorganisms around 
them, but through a signalling system involving the production of specific molecules they 
can, indeed, indirectly detect this (Bjarnsholt, 2013). This process is recognised as 
quorum sensing. Contrary to other Gram-negative bacteria, instead of using the usual 
autoinducer molecules (LuxIR system), S. maltophilia engages in a type of cell-to-cell 
signalling highly related to the diffusible signal factor (DSF)-dependent system of the 
phytopathogen Xanthomonas campestris (Fouhy et al., 2007). It was shown in a 
nematode model (Caenorhabditis elegans) that DSF plays an important role in functions 
attributed to antibiotic resistance and virulence. For example, interruption of DSF 
signalling in S. maltophilia will lead to a decrease in biofilm formation, loss of motility, 
and reduced production of extracellular proteases. Additionally, it was also 
demonstrated that DSF signalling of S. maltophilia can affect P. aeruginosa behaviour 
by modifying its biofilm formation and polymyxin- tolerance characteristics (Ryan et al., 
2008).  
Confocal microscopy has shown that a S. maltophilia clinical isolate (obtained from a CF 
patient) formed microcolonies in the presence of an extracellular matrix on CF sputum-
derived bronchial epithelial IB3-1 cell monolayers. In addition, the degree of adherence 
of clinical isolates to the bronchial epithelial cells varied among the clinical isolates, and 
there was no correlation between biofilm formation on polystyrene and on lung cells. 
This indicates that biofilm formation on abiotic surface does not necessarily reflect the 
same characteristics observed on biotic surfaces in animal models or human patients, 
as previously suggested (Worlitzsch et al., 2002).  
Environmental factors, such as presence of sodium phosphate, chloride concentration, 
pH, temperature, aerobic and anaerobic conditions, and the presence of copper and 
silver ions might also modulate S. maltophilia. Studies have shown that biofilm formation 
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has been favoured by the following conditions: presence of sodium phosphate (Brooke, 
2007); temperature growth of 32 °C, aerobic conditions in 6.0 % CO2 atmosphere (Di 
Bonaventura et al., 2007). Conversely, high concentrations of chloride seem to block 
important exopolysaccharide groups (Critchley et al., 2003), whereas copper-silver ions 
might bind to important biological molecules responsible for electrostatic and 
hydrophobic interactions (Shih and Lin, 2010). Both conditions were linked to a reduction 
of biofilm formation.      
 
1.5 Epidemiology and risk factors  
The clinical importance of S. maltophilia is enhanced by the emergence of multiple-drug 
resistance. This bacterium can be recovered from amply diverse sources, such as soil, 
plant roots, animals, invertebrate insects, water treatment and distribution system, 
sinkholes, lakes, rivers, washed salads, faucets, tap water, bottled water, hand-washing 
soap, contact lens solutions, ice machines, contaminated topical antiseptic and sink 
drains (Brooke, 2012; Zanetti et al., 2009; Denton and Kerr, 1998).  
Moreover, it is also able to form biofilms in water distribution systems, representing a 
potential risk for immunocompromised individuals (Sacchetti et al., 2009; Brooke, 2008). 
Once drains consist of aqueous environments, gradual deposition of bacteria might 
occur, leading to formation of biofilms. A study conducted in an U.S. teaching hospital 
collected samples from below the sink drainer, which not only revealed the presence of 
MDROs, including S. maltophilia, but also uncovered existence of thick biofilms (Brooke, 
2008). After testing the antimicrobial effects of 10.0 % peracetic acid and 3.0 % 
hydrogen peroxide (H2O2) to prevent contamination of a microfiltered water dispenser, it 
was noticed that 40 min post-treatment with H2O2 was most effective and reduced the 
number of S. maltophilia cells to <1 log CFU/100 mL (Sacchetti et al., 2009). 
Consequently, identification of these environmental sources is necessary to prevent 
and/or control bacterial contamination.  
The carriage of S. maltophilia in humans was also investigated. Interestingly, a faecal 
carriage rate of 6.0 % (14 out of 218 stool samples) was detected in outpatients with 
diarrheal illness or people they have come into contact with (Von Graevenitz and 
Bucher, 1983). In a small series, four out of 12 haematologic malignancy patients from 
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whom faecal samples were obtained were considered colonised by the bacterium. In 
contrast, the organism in question was only isolated in 2.9 % (n=2) of individuals from a 
control group (n=69 individuals) (Kerr et al., 1991).  
Multiple continents have documented an increasing isolation rate of S. maltophilia. For 
example, a study conducted in a range of U.S. hospitals from 1993 to 2004 revealed that 
S. maltophilia was, during this period, the most frequently isolated Gram-negative 
bacillus obtained from clinical isolates from patients in the intensive care unit (ICU) (4.3 
% of total of 74,394 isolates) (Lockhart et al., 2007). A German surveillance program 
conducted in ICUs indicated S. maltophilia as one of the 13 most frequent 
microorganisms responsible for nosocomial infections. Over a two-year period of 
investigation, the number of infections caused by S. maltophilia per 1,000 patient-days 
was 1.4 (range 0-7.6) (Meyer et al., 2006). In a tertiary care hospital in Taiwan, over a 
five-year period, increases of 49.0 % and 85.0 %, respectively, were noted in all types of 
nosocomial infection and nosocomial bloodstream infection caused by this pathogen 
(Tan et al., 2008). Another study conducted by SENTRY Antimicrobial Surveillance 
Program from 1997 to 2008 showed that the recovery rate of S. maltophilia from 
hospitalised patients with pneumonia varies (range 2.3 % - 3.3 %) between hospitals 
and geographic regions (Jones, 2010). In 2004, over 3,000 paediatric clinical isolates 
from three continents (North America, Latin America and Europe) were analysed by the 
SENTRY Antimicrobial Surveillance Program. The results indicated that S. maltophilia 
was among the top 15 isolated pathogens in North America and Latin America, but not 
in Europe (Fedler et al., 2006).  
In most cases S. maltophilia acquisition is nosocomial (Brooke, 2012; Falagas et al., 
2009). Molecular typing of isolates from hospitalised individuals or CF patients by 
pulsed-field gel electrophoresis, Enterobacterial Repetitive Intergenic Consensus - 
Polymerase Chain Reaction (ERIC-PCR), and semi-automated repetitive-sequence- 
based polymerase chain reaction (rep-PCR) assay (Diversilab®) uncovered a high 
genetic diversity between most strains, with occasional small clusters of close related 
isolates (Wu et al., 2011; Gülmez and Hasçelik, 2005; Valdezate et al., 2004; Denton et 
al.,1998). This finding indicates that S. maltophilia is acquired from an independent 
source, probably even prior to hospital admission, and the bacterium is then selected, 
during antimicrobial exposure, from the commensal flora. Further, a higher rate of 
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mutation is observed in clinical S. maltophilia isolates than in environmental ones. This 
fact suggests a possible adaptation mechanism to new or challenging environments, 
such as the CF airway (Taddei et al., 1997).   
Transmission of S. maltophilia infection to susceptible individuals can be avoided if 
important criteria concerning risk factors are considered. Currently, a number of risk 
factors associated with this pathogen have been identified, including underlying 
malignancy (Calza et al., 2003), the presence of indwelling medical devices (Metan et 
al., 2006), prolonged hospitalisation, ICU stay, chronic respiratory disease (Waters et al., 
2013; Waters et al., 2011), and compromised host immune system (Calza et al., 2003). 
Long-term therapy involving use of broad-spectrum antibiotics was also found to be an 
independent risk factor for stenotrophomonad infection (Paez and Costa, 2008).  
  
1.6 Antibiotic resistance 
S. maltophilia exhibits high-level intrinsic antibiotic resistance and several molecular 
mechanisms contribute to its drug resistance (Brooke, 2012).  
Beta-lactamases are a group of enzymes produced by some bacteria, which confer 
upon them resistance to the action of beta-lactam antibiotics (Abraham and Chain, 
1988). Lactamases are the main protagonists underpinning natural resistance to β-
lactams. This arises from the expression of two inducible β-lactamases, L1 and L2. L1 
belongs to Ambler class-B zinc dependent metalloenzymes, which hydrolyse all classes 
of β-lactams, but not monobactams (Avison et al., 2002). L2 is an Ambler class-A serine 
active-site β-lactamase that hydrolyses cephalosporins and monobactams, but it is 
inhibited by clavulanic acid and other β-lactamase inhibitors (Walsh et al., 1997). In 
general, these two chromosomal β-lactamases are induced when cells are exposed to 
β-lactams. Although the production of both β-lactamases is controlled by the same 
regulator (AmpR- ampicillin resistant), the expression of both enzymes is variable and is 
linked to chromosomal genes that are polymorphic even interspecies (Avison et al., 
2002). TEM1-type lactamases (first reported in 1965 from an Escherichia coli isolate 
from a patient in Temoneira), a plasmid-encoded constitutive broad-spectrum 2-
lactamase, can be related to mobile genetic elements and can exchange genetic 
material with other bacteria (Avison et al., 2000).  
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The active efflux of toxic substances and antimicrobial agents out of the bacterial cell 
has long been recognised as a resistance mechanism (Li et al., 1994). A membrane 
fusion protein, an energy-dependent transporter, and outer membrane proteins compose 
the efflux pump of S. maltophilia (Nicodemo and Paez, 2007; Alonso and Martínez, 
2000). In 2000, for the first time a multi-drug efflux pump of S. maltophilia was cloned 
and characterised. The system received the name SmeDEF (Alonso and Martínez, 
2000). Later on, it was verified that the SmeDEF multi-drug efflux pump was 
overexpressed in 33.0 % of clinical isolates, and it was correlated to the increase of 
tetracycline, choramphenicol, erythromycin, norfloxacin and ofloxacin minimum inhibitory 
concentrations (MICs) (Alonso and Martínez, 2001). Additionally, the SmeABC system, 
having SmeC as an alternative outer membrane multiple drug efflux protein of S. 
maltophilia, was described (Li et al., 2002). Recently, it has been shown that 
approximately 63.0 % of clinical S. maltophilia overexpressed SmeABC and exhibited 
high resistance to ciprofloxacin. These isolates were also typed using multilocus 
sequence typing, and a high degree of genetic diversity was observed among them (Cho 
et al., 2012).  
It has been suggested that aminoglycoside-modifying enzymes, temperature-dependent 
resistance due to modifications of the outer membrane, and efflux pumps are involved in 
aminoglycoside resistance (Brooke, 2012; Nicodemo and Paez, 2007). Enzymatic 
alterations of the aminoglycosides are correlated to a certain family of enzymes, which 
includes O-nucleotidyltransferases, O-phosphotransferases, and N-acetyltransferase 
(Looney et al., 2009). The strains producing the enzyme aac(6’)-Iz showed higher 
resistance to gentamicin (Lambert et al., 1999). Further, deletion of the aac(6’)-Iz 
acetyltransferase gene in a wild type S. maltophilia strain induced increased 
susceptibility to aminoglycoside antibiotics, including netilmicin, sisomicin, tobramycin, 
neomycin, and gentamicin (Li et al., 2003). Susceptibility variation to aminoglycosides 
and polymyxin was also associated to outer-membrane LPS features. S. maltophilia 
strains resistant to the aforementioned antibiotics tended to exhibit changes in LPS 
structure by surface expression of a high molecular weight polysaccharide component 
(McKay et al., 2003; Rahmati-Bahram et al., 1996).  
These, among other mechanisms (Table 1), are responsible for S. maltophilia antibiotic 
resistance.      
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Table 1 Summary of molecular mechanisms of antimicrobial resistance in S. maltophilia 
(modified from Brooke, 2012) 
 
Mechanisms 
 β-Lactamases chromosomally and plasmid encoded and on mobile elements 
 Multidrug efflux pumps, e.g. SmeDEF, SmeABC, associated with resistance to 
quinolones, tetracycline, chloramphenicol, erythromycin, aminoglycosides, and β-
lactams 
 Class 1 integrons and insertion element common region (ISCR) elements 
associated with resistance to trimethoprim-sulfamethoxazole 
 Phosphoglucomutase (SpgM) associated with resistance to polymyxin B, 
polymyxin E, nalidixic acid, gentamicin, vancomycin, ceftazidime, ticarcillin-
clavulanic acid, and piperacillin-tazobactam 
 Reduction in outer membrane permeability 
 Quinolone protection protein (SmQnr) determinant associated with resistance to 
quinolones 
 Modification of antibiotics 
 Mutation of bacterial topoisomerase and gyrase genes 
 
1.7 Treatment of infections 
Adoption of an adequate antimicrobial regimen to treat S. maltophilia infection remains a 
challenge due to the high-level intrinsic resistance, increasing resistance prevalence of 
this bacterium and doubts about data regarding in vitro susceptibility testing 
characteristics (Looney et al., 2009).   
The use of trimethoprim-sulfamethoxazole (also known as co-trimoxazole) alone, or in 
combination with other antimicrobial agents, is considered the first line of treatments for 
suspected or culture positive S. maltophilia infections. In vitro data indicates that 
trimethoprim-sulfamethoxazole acts as a bacteriostatic agent against this pathogen 
(Zelenitsky et al., 2005). However, patient hypersensitivity to this agent, due to the 
production of nitroso metabolites of sulfomethoxazole, might limit its use (Cheng et al., 
2008).  
β-lactam antibiotics show low activity, and given the previously mentioned resistance 
mechanisms, the use of penicillins and cephalosporins, particularly carbapenems, is 
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limited against S. maltophilia. In some instances, β-lactamase inhibitors, such as 
clavulanic acid, could actually increase the susceptibility of this bacterium to such agents 
(Muñoz Bellido et al., 1997). For example, for patients that cannot be treated with 
trimethoprim-sulfamethoxazole, ticarcillin-clavulanic acid could be considered a second 
therapeutic option (Falagas et al., 2008; Denton and Kerr, 1998). Although some in vitro 
activity is shown by the higher-class cephalosporins, such as ceftazidime, cefoperazone, 
and cefepime, there are increasing reports of strengthened resistance and low activity, a 
fact explained by the diversity of S. maltophilia isolates and the variable occurrence of 
inducible lactamases (Falagas et al., 2008).  Similarly, aminoglycosides also show poor 
activity against S. maltophilia due to high intrinsic resistance and, consequently, they 
play no role in monotherapy (Looney et al., 2009; Nicodemo and Paez, 2007).   
Conversely, the new fluoroquinolones (clinafloxacin, gatifloxacin, levofloxacin, 
moxifloxacin and sitafloxacin) exhibit superior in vitro activity than earlier quinolones 
(Nicodemo et al., 2004; Weiss et al., 2000; Valdezate et al., 2001a). Further, the 
tetracyclines doxycycline, minocycline and especially tigecycline have demonstrated 
good in vitro activity against clinical isolates of S. maltophilia (Sader et al., 2013; Tekçe 
et al., 2012; Looney et al., 2009), but clinical experience with this compound is limited 
(Samonis et al., 2012). 
Polymyxins are a type of antibiotic that have a polycationic peptide ring that interacts 
with anionic LPS molecules from the outer membrane of Gram-negative bacteria and, 
consequently, causes increase in cell-envelope permeability, leakage of cell contents 
and finally cell death (Schindler and Osborn, 1979; Newton, 1956). In the past decade, 
polymyxins have gained a role in the treatment of infections caused by multiresistant 
Gram-negative bacilli (Landman et al., 2008). By contrast, the real value of in vitro 
susceptibility testing data and toxicity effects with these drugs remain yet to be clarified 
(Looney et al., 2009; Nicodemo and Paez, 2007).  
Chloramphenicol is a bacteriostatic antimicrobial able to inhibit protein synthesis 
(Kasten, 1999). It has been reported that chloramphenicol combination therapy was 
successful in the treatment of three S. maltophilia meningitis cases (Feder, 1986). 
Unfortunately, clinical experience with this drug is quite limited and toxicity side effects 
should be kept in mind (Looney et al., 2009; Nicodemo and Paez, 2007). 
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1.8 Cystic Fibrosis 
Cystic fibrosis or mucoviscidosis is the most common fatal autosomal recessive disorder 
in the white population (O’Sullivan and Freedman, 2009). The incidence of CF varies 
around the world, but estimates show that 1 in 2,000-3,000 new borns in the European 
Union is affected by this genetic disorder (WHO, 2014).  
This disease is characterised by more than 1,700 different mutations in the cystic 
fibrosis conductance regulator (CFTR) gene, which encodes a small conductance ATP- 
and cAMP-dependent chloride channel that is mainly expressed in the apical border of 
epithelial cells lining exocrine glands (Rowe et al., 2005). Imbalance of ion concentration 
across the cell membrane due to absence of this channel will result in secretion of 
viscous fluids that eventually may result in plugged and atrophic ducts (Vankeerberghen 
et al., 2002). 
In the airways of CF patients, chloride secretion is decreased while sodium absorption is 
increased. Thus, the secreted mucous is thick, viscous and difficult to clear (O’Sullivan 
and Freedman, 2009). In addition, increased inflammatory response in the affected lung 
may be detectable through the occurrence of:  downregulation of epithelial interleukin 10 
(IL-10) production (an anti-inflammatory factor) (Bonfield et al., 1995); and increased 
degradation of annexin 1 (an anti-inflammatory protein present in bronchioalveolar 
lavage fluid) (Tsao et al., 1998). As a result, the CF lung provides a favourable 
environment for the development of chronic colonisation by diverse microorganisms (de 
Vrankrijker et al., 2010; Rowe et al., 2005).  
In past decades, due to the development of better antimicrobial therapies, nutritional 
support and lung transplantation, life expectancy for CF patients has increased to 
around 40 years (CFFPR, 2012). Other studies suggested a median survival age of up 
to 50 years to be a realistic scenario for these individuals (Dodge et al., 2007). 
Generally, CF patients reveal a progressive microbiological history. Typically, infants are 
infected by a limited spectrum of bacteria, mainly Staphylococcus aureus and 
Haemophilus influenzae. However, chronic colonisation by Pseudomonas aeruginosa 
becomes notable with age, and transient detection of other Gram-negative organisms 
also occurs (CFFPR, 2012; Hauser et al., 2011) (Figure 3).  
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Figure 3 Prevalence of respiratory pathogens in CF patients by age. Data source from Cystic Fibrosis 
Foundation Patient Registry (CFFPR), 2012.   
 
Chronic microbial infections lead to progressive lung function depression and pulmonary 
exacerbations, considered major causes of death in CF patients (Buzzetti et al., 2009; 
FitzSimmons, 1993). Pulmonary exacerbations are referred as intermittent episodes of 
acute worsening of symptoms, which may include clinical features such as increased 
cough and sputum production, shortness of breath, chest pain, loss of appetite, loss of 
weight and lung function decline (Goss and Burns, 2007).  
Pulmonary exacerbations in CF patients are related to diverse microorganisms, and one 
of them is S. maltophilia. The first report of S. maltophilia in a CF patient only occurred 
later in 1979 (Blessing et al., 1979). It is considered a ubiquitous organism, which can 
also be widely isolated from different nosocomial sources (Brooke, 2012; Denton and 
Kerr, 1998).    
Even though S. maltophilia commonly infects the respiratory tract of CF patients, its 
importance in the pathophysiology of CF lung disease remains unclear. Several 
worldwide CF centers have observed an increased prevalence of S. maltophilia (de 
Vrankrijker et al., 2010). Recently, it has been suggested that chronic colonisation by S. 
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maltophilia might be a risk for developing pulmonary exacerbation, death or lung 
transplant in CF patients (Waters et al., 2013; Waters et al., 2011). The question 
whether S. maltophilia is casuality related to the disease progression or a marker of the 
disease’s severity is still not defined. 
Therefore, isolation of this microorganism in CF patients becomes a cause for concern 
within the CF community, as previously described, due to the emergence of strains that 
might be resistant to current available antibiotic therapeutics suitable for treating CF.  
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1.9 Aim of the study 
S. maltophilia is a globally emerging environmental Gram-negative rod, whose 
prevalence has recently increased in CF centres worldwide (de Vrankrijker et al., 2010). 
It has recently been described as an independent risk factor for pulmonary exacerbation 
and has been associated with increased risk of death or lung transplantation in CF 
patients (Waters et al., 2013, Waters et al., 2011). In addition, this pathogen exhibits an 
inherently resistant profile against a plethora of antibiotic agents and it has the ability to 
form biofilms on abiotic (e.g. glass and plastics like polystyrene) and biotic (bronchial 
epithelial cells of host) surfaces (Brooke, 2012; Pompilio et al., 2010b). It is known that 
bacterial populations in CF patients are constantly exposed to a challenging 
environment and through repeated courses of antibiotic treatment. Therefore, strong 
diversification over time and the emergence of mutator phenotypes is likely to occur 
(Tenaillon et al., 1999). The significance of chronic and/or persistent colonisation of CF 
airway by S. maltophilia has not been sufficiently clarified, which leads to widely 
disparate views regarding the relevance of this bacterium in these patients (Goss et al., 
2004; Valdezate et al., 2001b). The efficacy of currently available therapeutics is 
diminishing due to the ongoing multi-drug-resistant nature of S. maltophilia. This, 
coupled with the lack of in-depth knowledge concerning drug resistance profiles of S. 
maltophilia, makes this microbe difficult to control in the CF population.    
This study attempts to investigate the relevance and importance of S. maltophilia in the 
CF-lung environment. Therefore, S. maltophilia was characterised and the following 
issues were investigated: 
 
1. Experiments for isolation and detection of S. maltophilia from sputum samples of 
CF patients - proper identification and antimicrobial susceptibility testing. 
Since other microorganisms such as P. aeruginosa and Aspergillus fumigatus can easily 
overgrow on solid media, isolation and identification of other potentially pathogenic 
microorganisms can often be challenging to microbiology laboratories. The first part of 
this dissertation focuses on the development and utilisation of a selective medium for 
improved isolation of S. maltophilia in comparison to conventional media. We also 
reported the activity of eight antimicrobial agents against this microorganism. 
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2. Phenotypic and genotypic characteristics of S. maltophilia isolates obtained from 
CF patients in comparison to other sources. 
The second part of this study is dedicated to investigating the genotypic diversity, 
specific assimilation, whole-cell fatty acid methyl ester profiles and protein composition 
of CF isolates, in comparison to other non-CF isolates and environmental samples.  
 
3. Evaluation of specific immune response against S. maltophilia in CF patients. 
In general, chronic exposure to a pathogen leads to a specific immune response. 
Infection markers for S. maltophilia, such as antibodies, may be helpful to determine the 
state of colonisation/infection by this bacterium in CF patients. Thus, we developed a 
quantitative immunofluorescence assay for the detection of specific S. maltophilia 
antibodies in serum from CF patients. We also verified if there was a correlation 
between S. maltophilia antibody titres and different categories of colonisation (never S. 
maltophilia or P. aeruginosa, intermittent and chronic).  
 
4. Adaptation and dynamics of S. maltophilia bacterial population in CF airways 
during chronic infection.  
Some studies have reported high prevalence of P. aeruginosa mutators in chronically 
colonised CF patients. Hypermutation is thought to play a role in the evolution of 
antibiotic resistance, which consequently results in limitation of antibiotic-therapy 
options. To expand understanding on the matter of S. maltophilia adaptation to CF 
airways, we examined the genotypic diversity, mutation frequency and antibiotic 
resistance of S. maltophilia isolates from chronically colonised CF patients.  
 
5. Evaluation of EGCg as an antimicrobial agent against S. maltophilia  
Finally, we evaluated the antimicrobial activity of EGCg, the most abundant polyphenol 
present in green tea, against CF S. maltophilia isolates and S. maltophilia acute 
pulmonary infection induced in wild type and Cftr mutant mice. We further determined 
EGCg effects on biofilms in comparison to those of colistin (COL). 
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2 Material and methods 
2.1 Antimicrobial agents 
Table 2 Antimicrobial agents 
Antimicrobial agents Company 
Amphotericin B Sigma-Aldrich, St. Louis, USA 
Ampicillin sodium salt Sigma-Aldrich, St. Louis, USA 
Colistin (27655-1G) Sigma-Aldrich, St. Louis, USA 
Gernebcin (tobramycin – 40 mg/mL) InfectoPharm, Heppenheim 
Imipenem ZIENAM, Merck Sharp&Dohme, India 
Rifampicin (R3501-250 mg) Sigma-Aldrich, St. Louis, USA 
Vancomycin Ratiopharm, Ulm 
Colistin, Ceftazidime, Fosfomycin, 
Levofloxacin, Moxifloxacin, 
Ticarcillin/clavanulate, 
Trimethoprim/sulfametaxazole, Tigecycline, 
Tobramycin (MIC test strips) 
 
 
Liofilchem, Roseto degli Abruzzi, Italy 
 
2.2 Chemical products 
Table 3 Chemical products 
Chemical products Company 
Acetic acid Merck, Darmstadt 
Agar Carl Roth, Karlsruhe 
Aqua sterile distilled B. Braun, Melsungen 
Boric acid Carl Roth, Karlsruhe 
Blood agar base (Fa. CM 55) Oxoid, Wesel 
Calcium chloride (CaCl2) Fluka Chemie AG, Switzerland 
Cholesterol/cholesterin Carl Roth, Karlsruhe 
Crystal violet Sigma-Aldrich, St. Louis, USA 
Dimethyl sulfoxide (DMSO) Sigma-Aldrich, St. Louis, USA 
Disodium hydrogen phosphatedihydrate 
(Na2HPO4. 2H2O) 
Merck, Darmstad 
Dipotassium hydrogen phosphate 
(K2HPO4) 
Merck, Darmstad 
Epigallocatechin-3-gallate (EGCg E4143-
50mg) 
Sigma-Aldrich, St. Louis, USA 
Ethanol ≥99.8 %,p.a. Carl Roth, Karlsruhe 
Ethidium bromide Carl Roth, Karlsruhe 
Ethylenediaminetetraacetic acid (EDTA) Carl Roth, Karlsruhe 
Magnesium sulfate heptahydrate  
(MgSO4. 7H2O) 
Merck, Darmstad 
Menadione Sigma-Aldrich, St. Louis, USA 
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Methanol Baker, USA 
n-Hexan Merck, Darmstad 
Phosphate buffer saline pH 7.4 
supplement with Tween 20 
(PBS/Tween20) 
Sigma-Aldrich, St. Louis, USA 
Potassium dihydrogen phosphate 
(KH2PO4) 
Merck, Darmstad 
Saponin Sigma-Aldrich, St. Louis, USA 
Sodium chloride (NaCl) Carl Roth, Karlsruhe 
Sodium hydroxide (NaOH) Merck, Darmstadt 
Sodium hypochlorite (NaClO) Carl Roth, Karlsruhe 
tert-Butylmethylether Merck, Darmstad 
Trimethylsulfonium hydroxide Macherey-Nagel, Düren 
Tris(hydroxymethyl)aminomethane (Tris) Carl Roth, Karlsruhe 
Ultrapure MilliQ water (0.22 µm filter) Merck, Darmstad 
2,3-bis (2-methoxy-4-nitro-5-sulfophenyl)-
2H-tetrazolium-5-carboxanilide inner salt 
(XTT) 
Sigma-Aldrich, St. Louis, USA 
5-Fluoro-2’- deoxyuridine (FUDR) Calbiochem, Darmstadt 
100 base pair DNA ladder (100 BP 
Ladder, 100 μg) 
GE Healthcare, Little Chalfont, UK 
 
2.3 Buffer solutions, solutions and media (solid and liquid) 
Candida chrom agar (Brillance)  Typical formula 
(Oxoid, Wesel, Germany)   4 g/L peptone 
13.6 g/L chromogenic mix 
13.6 g/L agar 
pH 6.0 ± 0.2 
 
Columbia agar with sheep blood   Typical formula 
(Oxoid, Wesel, Germany)   23 g/L special peptone 
1 g/L starch 
5 g/L NaCl 
10 g/L agar 
pH 7.3 ± 0.2 
 
Luria-Bertani (LB) agar   10 g/L trypton (Becton Dickinson, USA) 
5 g/L yeast extract (Becton Dickinson, USA) 
10 g/L NaCl (Merck, Darmstadt) 
15 g/L agar (Merck, Darmstadt) 
Sterilise by autoclaving the solution at 121 °C 
for 20 min. 
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Luria-Bertani (LB) broth   10 g/L trypton (Becton Dickinson, USA) 
5 g/L yeast extract (Becton Dickinson, USA) 
10 g/L NaCl (Merck, Darmstadt) 
Sterilise by autoclaving the solution at 121 °C 
for 20 min. 
 
Lysis buffer      3.3 mL 5M NaOH 
(C. elegans assay)    2.8 mL 12 % NaOCl 
3.9 mL MilliQ water 
 
Malt extract agar plate   Typical formula 
(Oxoid, Wesel, Germany)    30 g/L malt extract peptone 
5 g/L mycological peptone 
15 g/L agar 
pH 5.4 ± 0.2 
 
MacConkey agar plate   Typical formula 
(Oxoid, Wesel, Germany)    20 g/L peptone 
10 g/L lactose 
5 g/L bile salts 
5 g/L NaCl 
0.075 g/L neutral red 
12 g/L agar 
pH 7.3 ± 0.2 
 
Müller-Hinton agar (MHA)   Typical formula 
(Oxoid, Wesel, Germany)   300 g/L beef, dehydrated infusion of 
17.5 g/L casein hydrolysate 
1.5 g/L starch 
17 g/L agar 
pH 7.3 ± 0.2 
 
Müller-Hinton broth (MHB)   Typical formula 
(Oxoid, Wesel, Germany)    300 g/L beef dehydrated infusion of 
17.5 g/L casein hydrolysate 
1.5 g/L starch 
Add 21 g to 1 L of distilled water and autoclave 
at 121 °C for 20 min. Adjust pH to 7.3. 
 
M9 Buffer     3 g/L KH2PO4 
(C. elegans assay)    6 g/L Na2HPO4 
5 g/L NaCl 
1 mL/L 1 M MgSO4 
Sterilise by autoclaving at 121 °C for 20 min. 
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Nematode growth medium   3 g NaCl 
(NGM) agar (C. elegans assay)  17 g agar 
2.5 g peptone 
Dissolved in 975mL of distilled water and 
autoclave for 121 °C for 20 min. 
After autoclaving procedure, add under sterile 
conditions: 
1 mL 1M CaCl2 
1 mL of 5 mg/mL cholesterol dissolved in 
absolute ethanol 
25 mL 1M KPO4 
1 mL 1M MgSO4 
 
NGM liquid medium    3 g NaCl 
(C. elegans assay)      2.5 g peptone 
Dissolved in 975 mL of distilled water and 
autoclave for 121 °C for 20 min. 
After autoclaving procedure, add under sterile 
conditions: 
1 mL 1M CaCl2 
1 mL of 5 mg/mL cholesterol dissolved in 
absolute ethanol 
25 mL 1M KPO4 buffer pH 6.0 (108.3 g 
KH2PO4, 35.6 g K2HPO4 to 1 L of H2O) 
1 mL 1M MgSO4 
 
Tris/borate/EDTA 1M solution buffer 121.1 g/L tris 
(electrophoresis)              61.8 g/L boric acid 
7.4 g/L EDTA 
Sterilise by autoclaving the solution at 121 °C 
for 20 min. Adjust pH to 8.35-8.4. 
 
Trypticase soya agar (TSA)  Typical formula 
(Becton Dickinson, USA)   15 g/L pancreatic digest casein 
5 g/L papaic digest of soybean 
5 g/L NaCl 
15 g/L agar 
pH 7.3 ± 0.2 
 
Tryptone soya broth    Typical formula 
(Oxoid, Wesel, Germany)   17 g/L pancreatic digest of casein 
3 g/L enzymatic digest of soya bean 
5 g/L NaCl 
2.5 g/L K2HPO4 
2.5 g/L glucose 
Add to 1 L of H2O and sterilise by autoclaving 
at 121 °C for 20 min. Adjust pH to 7.3. 
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2.4 Commercial kits and solutions 
 
Table 4 Commercial kits and solutions 
Commercial kits and solutions Company 
API 20 NE strips bioMérieux, Basingstoke, UK 
Aqua 10 mL B. Braun, Melsungen 
LIVE/DEAD® BacLight™ bacterial viability 
and counting kit 
life technologies, Darmstadt 
DiversiLab® general Fingerprinting bacterial 
kit (30 samples) 
bioMérieux, I’Etoile, France 
DiversiLab® DNA chip and reagents bioMérieux, I’Etoile, France 
Fluoline H Immunoglobulin G (IgG) 
fluorescence (Ref 75 603) 
bioMérieux, Nottingham, UK 
Propidium iodide 1mg/mL life technologies, Darmstadt 
Taq PCR Core Kit 
(10× PCR Buffer, 25mM MgCl2, 
deoxynucleotide triphosphate (dNTP) Mix - 
10mM of each ) 
QIAGEN, Hilden 
Matrix Vitek MS-CHCA bioMérieux, I’Etoile, France 
SPUTASOL Oxoid, Wesel 
Target Vitek bioMérieux, I’Etoile, France 
UltraCleanTM microbial DNA isolation kit 
 
Mo Bio Laboratories, Carlsbad, USA 
Phosphate buffer saline (PBS) 10× solution Gibco, Grand Island, USA 
RPMI medium supplement with HEPES (L-
Glutamine + 25mM HEPES) 500 mL 
Gibco, Grand Island, USA 
 
Table 5 Equipment 
Equipment Company 
Agilent 2100 bioanalyzer Agilent Technologies, Santa Clara, USA 
Agitator (IKAMAG®REO) Ika Labortechnik, Staufen, 
Bioanalyzer Chip Vortexer (MS 3) Ika Labortechnik, Staufen 
Biosafety Cabinet Type II, Category 2, 
Hera Safe 
Thermo Scientific, Waltham, USA 
Capillary FID GC system   SRI instruments, Torrance, USA 
Central processing unit (connected to 
Agilent 2100 bioanalyzer) 
Hewlett-Packard, Palo Alto, USA 
Centrifuge (5415D) Eppendorf, Hamburg 
Centrifuge (Heraus Megafuge 16) Thermo Scientific, Waltham, USA 
Certomat U/H incubator shaker B. Braun, Melsungen 
Computer software Microsoft Windows XP 
Electric pipet-aid (0.1 mL to 200 ml) Hirschmann Laborgeräte, Eberstadt 
Horizontal electrophoresis gel box Carl Roth, Karlsruhe 
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Freezer -20 °C (GGPv 6590) Liebherr, Bulle, Switzerland 
Gel photo documentation system Intas Science Imaging Instruments 
GmbH,  Göttingen 
Hewlett Packard 5890 Series II Gas 
Chromatograph System with Computer/w 
software 
Hewlett Packard, Palo Alto, USA 
Incubator Binder, Tuttlingen 
Incubator Heraues Instruments - Function 
Line 
Thermo Scientific, Waltham, USA 
Inhalator  Pari Boy ® SX, Starnberg 
Inverse confocal laser scanning 
microscope 
Opera system, Perkin-Elmer Cellular 
Technologies, Waltham,  USA 
MicroScan® Walkaway system Siemens, Erlangen 
Microscope Axio observer Zeiss, Jena 
Microscope Wild M5A Heerbrugg, Switzerland 
Microtitreplate reader (Sunrise-96-well 
plate) 
Tecan, Männedorf 
Monitor 17 inches Hewlett-Packard, Palo Alto, USA 
Multi-channel  pipette (8-channel) 
adjustable volume (30-300 µL) 
Thermo Scientific, Waltham, USA 
Nanodrop(ND- 1000) spectrophotometer Peqlab Biotechnologie GmbH, Erlangen 
Pipette (adjustable volume, 0.5-50 µL) Carl Roth, Karlsruhe 
Pipette (adjustable volume, 0.5-10 µL) Carl Roth, Karlsruhe 
Pipette (adjustable volume, 2-20 µL) Eppendorf, Hamburg 
Pipette (adjustable volume, 10-100 µL) Eppendorf, Hamburg 
Pipette (adjustable volume, 20-200 µL) Eppendorf, Hamburg 
Pipette (adjustable volume, 100-1000 µL) Eppendorf, Hamburg 
Power supply Vokam (SAE 2761) Shandon Scientific, London, UK 
PTC-100 Programmable Thermal 
Controller (ERIC-PCR reaction run) 
MJ Research, St. Bruno, Canada 
pH meter (pH 522) WTW, Weilheim 
Refrigerator (FKU1800) Liebherr, Bulle, Switzerland 
Balance (AW series) Shimadzu, Kyoto, Japan 
Balance (Tuning-Fork Sensor) Shinko Denshi, Tokyo, Japan 
Small Animal Laryngoscope Model LS-2 PennCentury, Wyndmoor, USA 
Thermocycler FlexCycler (rep-PCR 
reaction run) 
Analytik Jena, Jena 
Vitek® Mass Spectrometer Axima, Shimadzu Corporation, Kyoto, 
Japan 
Vortex Genie 2TM (G560-E) Bender & Hobein AG, Baden-
Württemberg 
Water bath Köttermann Labortechnik, Hänigsen 
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2.5 Oligonucleotides 
The primers used in DNA amplification for identification and for Enterobacterial repetitive 
Intergenic Consensus - polymerase chain reaction (ERIC-PCR) were purchased from 
Tib Molbiol (Berlin, Germany). 
 
Table 6 Oligonucletide primers for amplification of 16S rRNA gene 
Oligonucleotide Sequence Amplicon size 
(base pair – bp) 
DG74 5′-AGG AGG TGA TCC AAC GCG A-3′ 300 
Rw01 5′-AAC TGG AGG AAG GTG GGG AT-3′ 350 
 
 
Table 7 Oligonucleotides for amplification priming in Enterobacterial Repetitive 
Intergenic Consensus - polymerase chain reaction (ERIC-PCR) 
Oligonucleotide Sequence Annealing 
temperature (TA) 
Primer ERIC-1 5’-ATG AAG CTC CTG GGG ATT CAC-3’ 55 °C 
 
Primer ERIC-2 5’-AGG TAA GTG ACT GGG GTG AGC G-3’ 55 °C 
 
2.6 Improved detection of S. maltophilia in sputum sample and susceptibility 
testing profiles 
2.6.1 Culture on conventional media 
A total of 623 sputum samples from 165 CF patients admitted to the Department of 
Paediatric Pulmonology from the Children’s Hospital and West German Lung Centre at 
University Hospital Essen, Essen (Germany) were investigated. Growth of S. maltophilia 
was verified by inoculating 10 μL of sputum onto routinely implemented media. In cases 
where sputum exhibited a very mucoid consistency, an equal volume of SPUTASOL 
(LIQUID) was added, and this solution was vigorously homogenized on a vortex mixer at 
room temperature. The solid media used were Columbia agar with sheep’s blood, 
chocolate blood agar, MacConkey agar, Candida chrome agar (Brilliance), and malt 
agar. The incubation period for all media was 48 h at 35 °C, with the exception of malt 
agar, which was incubated for an additional eight days at room temperature. 
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2.6.2 Culture on selective media 
Steno medium agar (SMA) was formulated as follows: 40 g of blood agar base to 1 L of 
distilled water, which was autoclaved for 15 min at 121 °C. The medium was allowed to 
cool to 50-60 °C in a water bath and the pH was adjusted to 7.0±0.2. Freshly filtered 
sterilised solutions of amphotericin B, imipenem, and vancomycin were added to make 
final concentrations of 2.5 mg/L, 32 mg/L, and 10 mg/L, respectively. The medium was 
transferred into petri dishes (diameter, 90 mm) and stored for 3 weeks at 4 °C. Medium 
validation was carried out by culturing S. maltophilia (ATCC 13637) and an imipenem-
susceptible Klebsiella pneumonia reference strain (ATCC 10031) for as long as 25 days. 
Through this quality control, it was possible to demonstrate that SMA remains stable for 
up to 21 days. Imipenem activity is significantly reduced after this period of time. Aliquots 
from fresh sputa samples (not older than three days and stored at 4 °C) were plated 
onto SMA and incubated aerobically at 35 °C for up to 48 h. 
 
2.6.3 Identification of S. maltophilia clinical isolates 
Isolates that grew on SMA agar were identified by standardised biochemical laboratory 
methods, including MicroScan® Walkaway and API 20 NE strips. Fresh cultures of 
S. maltophilia isolates on Columbia agar with sheep blood were used to carry out DNA 
extraction. S. maltophilia ATCC 13637 reference strain was used as a quality control. 
Genomic DNA extraction was performed with the UltraCleanTM microbial DNA isolation 
kit in accordance with the manufacturer’s instructions. The extracted DNA was stored at 
-20 °C until amplifications were conducted. All clinical isolates were confirmed to be 
S. maltophilia by amplifying the genomic region that codes for the 16S ribosomal 
subunit, using the primers described in Table 6. Amplification reactions were conducted 
in a 50 µL final volume containing 1 µL of 10mM d-NTP mix, 5 µL of 10× PCR buffer, 
0.5 µL (100µM) of each primer, 0.25 µL of 1.5 Unit (U) Taq DNA polymerase (Qiagen), 
37.75 µL double distilled water and 5 µL DNA (5 ng/µL). The PCR program was carried 
out as follows: 25 cycles of denaturation step at 95 °C for 30 s, annealing of the primer 
at 50 °C for 60 s, and 2 min of extension at 72 °C. The last cycle extension was at 72 °C 
for 5 min. Amplicons were sent to LGC Genomics (Berlin, Germany) for further 
sequencing. 
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2.6.4 Susceptibility testing against eight antimicrobial agents 
Antibiotic susceptibility of 65 S. maltophilia isolates obtained from 33 CF patients was 
analysed. MIC test strips with stable continuous gradient of ceftazidime, colistin, 
fosfomycin, levofloxacin, moxifloxacin, ticarcillin-clavulanate, trimethoprim-
sulfamethoxazole, and tigecycline were used. Minimum inhibitory concentration (MIC) 
tests were conducted following the Clinical and Laboratory Standards Institute (CLSI) 
guidelines (M07-A8) (CLSI, 2009). S. maltophilia ATCC 16637 reference strain was 
used for quality assurance purposes. An adjusted suspension of each isolate to the 
density of 0.5 McFarland standard was plated on Müller-Hinton agar (MHA) in three 
directions to ensure uniform growth. MIC test strips were applied once the agar surface 
was completely dry. The plates were incubated for 24 h at 35 °C. The MIC was 
interpreted (according to the manufacturer's guidelines) as the zone of growth inhibition 
that intersected the MIC test strip. CLSI has established interpretive criteria for the 
characterisation of susceptibility breakpoints of S. maltophilia, for all of the above 
antimicrobial agents except for colistin and moxifloxacin. Susceptibility breakpoints 
established for P. aeruginosa were applied, when testing colistin and moxifloxacin 
(Andrews, 2009; CLSI, 2009). 
 
2.7 Genotyping 
All the clinical sputum samples from CF and ICU patients included in this study were 
collected as part of the routine screening procedure of the University Hospital of Essen, 
Essen, Germany. A total of 102 S. maltophilia isolates (CF=71, ICU=20, 
environment=11) were identified and genomic DNA from each sample was isolated as 
previously described. ATCC13637 was used to assure quality control. 
 
2.7.1 Repetitive-Sequence-Based Polymerase Chain Reaction (rep-PCR) 
Diversilab® (DL) bacterial DNA fingerprinting kit, which included rep-PCR master mix 1, 
bacterial primers, and kit-specific positive and negative controls, was used following the 
protocol recommended by bioMérieux. A total of 35 ng of genomic DNA, 2.5 U of 
AmpliTaq DNA polymerase, and 1.5 µL of 10× PCR buffer were added to the rep-PCR 
master mix to achieve a final volume of 25 µL. Thermal cycling parameters were as 
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follows: initial denaturation at 94 °C for 2 min, 35 cycles of denaturation at 94 °C for 30 
s, annealing at 60 °C for 30 s, extension at 70 °C for 90 s, and final extension at 70 °C 
for 3 min. Analysis of rep-PCR products was conducted by a DL system, in which 
amplified fragments of various sizes and intensities were separated electrophoretically 
and detected on a microfluidics Labchip with an Agilent 2100 Bioanalyzer. Loading 
volume was 1 µL. Electrophoresis data was examined through the internet-based DL 
software (version 3.4). Dendrograms were based on Pearson correlation coefficients, 
which generated a scatter plot and a virtual gel image. Isolates with a similarity of ≥ 95 
% were considered as clinically related, and isolates with a similarity >98 % were 
considered as “indistinguishable” from one another. 
 
2.7.2 Enterobacterial Repetitive Intergenic Consensus - Polymerase Chain 
Reaction (ERIC-PCR) 
Amplification reactions were performed in a final volume of 50 µL of PCR mixture 
prepared for each isolate, containing final concentrations of 1×PCR buffer, 4mM MgCl2, 
0.5µM of each primer (Table 7), 80µM dNTP mixture, 1.25 U of Taq polymerase, sterile 
distilled aqua and 10 ng/µL extracted DNA (Finger et al., 2006). The Taq PCR Core Kit 
was used to carry out this DNA amplification. A positive control (ATCC 13637) was used 
in each run. After 5 min of denaturation at 94 °C, 45 cycles were run as follows: 
denaturation at 96 °C for 1 min, annealing at 55 °C for 2 min, extension at 72 °C for 
1 min, and a final extension step at 72 °C for 5 min. The amplification products were 
analysed by electrophoresis using 1 % agarose gels. A 100bp DNA ladder was used as 
a molecular size marker. Band analysis of the amplicons obtained was performed using 
the Phoretrix 1 D software (TotalLab Ltd, Newcastle upon Tyne, UK, v12.2), whereas 
cluster analysis was conducted with Phoretrix 1D Pro (v12.2). Band pattern similarity 
was estimated by means of the Pearson correlation coefficient and clustering of patterns 
was defined using the Ward algorithm. Only five environmental isolates were suitable for 
use in this assay due to sample contamination or reading error. 
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2.8.3 Calculation of discriminatory power  
The discriminatory power of DL and ERIC-PCR were calculated using Simpson's index 
of diversity (SID) and confidence intervals (CI). SID calculates the probability that two 
unrelated strains sampled from the test population will be placed into different typing 
groups. The quantitative correspondence between typing methods was assessed based 
on adjusted Rand (AR) and Wallace (W) coefficients (Severino et al., 2011; Pinto et al., 
2008; Carriço et al., 2006). The AR index provides quantification of congruence; 
whereas the W coefficient assists in the calculation of the probability that two strains 
classified as the same type by one method would also be classified as the same type by 
other methods. Since the Rand coefficient leads to an overestimation of agreement 
amongst typing methods, its use was avoided. Index of diversity and degree of 
congruence between typing methods were estimated using an online application 
(http://www.comparingpartitions.info/; accessed on 01/15/2014).  
 
2.8 Profiles of cellular fatty acid methyl esters (FAME) through gas 
chromatography (GC) 
Reference strains ATCC13637 and DSM8573, environmental samples (n=11), as well 
as clinical isolates obtained from CF (n=71) and ICU (n=20) patients were cultured on 
TSA and incubated at 28 °C for 24 h. Approximately 100 mg of culture material (wet 
weight) were used. Experiments were performed as previously described (Miller and 
Berger, 1985; Müller et al., 1998). Bacterial pellets were saponified in 30.0 % (w/v) 
sodium hydroxide (NaOH) dissolved in water. Then, cellular fatty acids were methylated 
(hydrochloric acid in methanol), extracted (n-hexane in methyl tert-buthyl-ether), and 
cleaned (NaOH). The fatty acid methyl esters (FAMEs) were processed on a Hewlett 
(Avondale, PA) gas chromatographic system; series II gas chromatograph equipped with 
a split inlet and flame ionisation detector, automatic sampler 6890, and fused-silica 
capillary column (Ultra 2, HP 19091 B-102; 25m by 0.2 mm with 5.0 % cross-linked 
phenylmethyl silicone) as the stationary phase. The instruments were coupled with a HP 
Vectra XU 5/90C Computer loaded with 3365 series II Chemstation (version 3.34) 
software. The parameters conformed to those recommended by MIDI system (Microbial 
Identification System, operating manual, version 5.0, 1995, MIDI, Inc.): hydrogen was 
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used as a carrier gas, sample volume 2 µL, split ratio 1:100, injector temperature of 250 
°C (temperature detector 300). Temperature program ramped from 170 °C to 260 °C at 
5 °C/min and from 260 °C to 310 °C at 40 °C/min followed by an isotherm phase at 
310 °C for 4 min. A ballistic increase to 310 °C allowed column cleaning during a hold of 
two min. The Sherlock Software Package of MIDI (version 1.06) performed analyses 
together with Sherlock System Software (Part 1300) and the Library Generation 
Software (LGS, Part 1303). Sherlock Pattern Recognition algorithm was used to obtain 
quantitative and qualitative (peak identification) information from the chromatography 
data. Cluster analysis through unweighted pair matching (Euclidean distance) and 
principal component analysis of the chromatographic data were performed using the 
implemented LGS software. The peak area index, which represents the amount of fatty 
acids produced in the broth culture during bacterial growth, was determined as follows: 
total peak area/solvent peak area × 10,000 (Müller et al., 1998). The unpaired non-
parametric Mann-Whitney U test (significance set at P <0.05) was used to address the 
fatty acid production differences amongst CF, ICU and environment isolates (Prism 5.0 - 
Graph Pad Software, San Diego, CA, USA). 
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Figure 4 Sample preparation flow chart for GC experiments. 
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2.9 Matrix-assisted Laser Desorption Ionisation-Time of Flight Mass Spectrometry 
(MALDI-TOF MS) 
Material from fresh colonies from an overnight culture of each of the S. maltophilia 
isolates (CF patient isolates, n=69; ICU patient isolates, n=20; environment isolates, 
n=11) were transferred to two sample position spots on a disposable MALDI-TOF MS 
target slide (bioMérieux). Two CF samples and the environmental reference strain were 
not suitable for use in this assay due to sample contamination or reading error. 
Subsequently, the bacterial sample was overlaid with 1 µL of α-cyano-4-hydroxy 
cinnamic acid as organic matrix solution (VITEK MS-CHCA) and allowed to dry at room 
temperature. Measurements were performed on a Shimadzu AXIMA Assurance TM mass 
spectrometer and analysed with the Vitek® MS Plus identification system provided by 
bioMérieux. The mass spectrometer is equipped with a 20-Hz N2-LASER and an ion-
source with an acceleration voltage of 20 kV and extraction delay time of 200 ns. 
Spectra were acquired in positive ion mode and within a mass range of 2,000 to 20,000 
Da. Data from a minimum of 500 shots per sample spot were collected. The acquired 
spectra were compared to the Vitek MS RUO® system database. The acquired spectra 
were compared to the Vitek MS V2.0 Knowledge Base for Clinical Use. The spectra of 
the tested samples were matched against the SuperSpectra® included in the database. 
Peak pattern that produced a match with the identification data with a confidence level 
exceeding 80.0 % were considered significant and were displayed. The reference strain 
Escherichia coli ATCC 8739 was used to calibrate and to validate the mass 
spectrometer of each used target. All peak lists of MALDI-TOF mass spectra were 
processed to perform hierarchical cluster analysis (HCA), based on Euclidean distance 
for Ward's method, in order to calculate the degree of similarity among the isolates. 
Principal component analysis (PCA) of the processed peak lists was performed as a 
multivariate analysis to identify the first three principal components and also to uncover 
differences of the isolates in respect of these components. The data were processed by 
creating peak lists, ranging from 2,000 to 20,000 Da with intervals of 5 Da, containing 
either zero values (absence of peak) or the peak´s relative intensity values. After 
importing the peak lists into the software DataLab®, the data were standardised prior 
calculation of the distance matrix. The result of the HCA was visualised as a 
dendrogram. PCA was applied to determine if the dimension of the parameter space 
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spread up by all possible m/z values may be reduced to fewer dimensions of which the 
first three most important principle components explain most of the variability of the data. 
In the three dimensional plot each isolate is represented as a dot in the PC1-3 space. 
Clustering in respect of PCA is not the same as in HCA because of different 
mathematical approaches. PCA is more sensitive to reveal differences amongst 
individuals, whereas HCA, in contrast, is more sensitive to demonstrate similarities. 
 
2.10 Dynamic adaptation of S. maltophilia in chronically colonised CF patients 
2.10.1 Molecular typing by repetitive-sequence-based-PCR (rep-PCR) 
In order to verify the molecular diversity of the isolates (n=90), rep-PCR was performed 
using the DL bacterial DNA fingerprinting kit, following the manufacturer’s 
recommendations as previously described. We used ATCC 13637 reference strain as a 
quality control. Subculture stability and reproducibility of rep-PCR results were defined 
by the average similarity of >98 % of three different colonies obtained at three time 
points (1, 5 and 10 days). 
 
2.10.2 Mutation frequency assay 
Frequency of mutations conferring rifampicin resistance were estimated as described 
(Turrientes et al., 2010). S. maltophilia isolates (n=90) obtained from chronically 
colonised CF patients were cultured on blood agar plates and incubated for 24 h at 
35 °C. One independent colony from each blood agar plate was inoculated in three 
glass tubes containing 2 mL of LB broth, and further incubated for 24 h in an orbital 
agitation incubator at 35 °C (150 rpm). Subsequently, aliquots (100 µL) of a 10-6 dilution 
from each overnight culture were cultured on LB agar plates. An additional 500 µL of 
these overnight cultures were seeded into LB agar plates supplemented with rifampicin 
(250 g/L). Colony counts of LB and LB-rifampicin agar plates were performed after 24 h 
and 48 h incubation, respectively. The result for each isolate derives from the mean 
value obtained from three independent experiments. If any of the following conditions 
were met: no colonies were detected on LB-rifampicin agar plates, suspicion of 
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contamination, or ten times difference in the standard deviation of the mutation 
frequencies from the three independent experiments; the experiments were repeated. In 
these cases, only the new values reported in the three new experiments would be 
included. S. maltophilia ATCC13637 reference strain (mutation frequency f= 1.5 ×10-7) 
was used as a control. The mean number of mutants for each isolate was calculated. 
Isolates were classified into four categories based on their mutation frequencies: 
hypomutator (f ≤ 8 × 10-9), normomutator (8 × 10-9< f < 4× 10-8), weak hypermutator (4 × 
10-8< f < 4× 10-7) and strong hypermutator (f ≥ 4 × 10-7) (Turrientes et al., 2010). 
 
2.10.3 Antimicrobial susceptibility testing 
In order to verify if the isolates become more resistant over time, in vitro activities 
of ceftazidime, colistin, co-trimoxazole, fosfomycin, levofloxacin, moxifloxacin, 
tigecycline and tobramycin, were tested against all 90 S. maltophilia isolates. 
Susceptibility testing was performed using MIC test strips and resistance breakpoints 
were those of CLSI guidelines (M07-A8). For colistin, we used the breakpoints 
established for P. aeruginosa. S. maltophilia ATCC 16637 was tested for quality 
assurance purposes. A suspension with adjusted density of 0.5 McFarland standard was 
plated on MHA. MIC was read after incubation at 35 °C for 24 h. According to the 
manufacturer's guidelines, the zone of growth inhibition that intersected the MIC test 
strip was interpreted as the MIC. Fisher’s test was used for comparison of resistance 
between nonmutator (hypomutator and normomutator) and mutator (weak hypermutator 
and strong hypermutator) groups. 
 
2.11 Antibody titres against S. maltophilia in patients with CF - development of a 
quantitative immunofluorescence assay (IFA) 
Serum samples from CF patients belonging to the University Hospital Essen 
epidemiological surveillance bank and healthy subjects were randomly selected and 
analysed. The serum collection consisted of a single specimen per patient. Based on 
their sputum culture status, CF individuals were classified within the study period as 
previously described (Döring and Høiby, 1983): chronic, two or more positive sputum 
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cultures for S. maltophilia in a given year; intermittent, one positive culture for 
S. maltophilia in a given year or previous positive culture; and never S. maltophilia, 
absence of positive culture for S. maltophilia. Additional groups were composed of: “CF 
patients never S. maltophilia/P. aeruginosa” and “CF patients never S. maltophilia but 
chronic P. aeruginosa”. These were included to verify potential cross-reactivity with 
P. aeruginosa antibodies. Serologic response was measured by indirect IFA using 
S. maltophilia (ATCC13637) whole cells as the antigen, which was later visualised by 
Fluoline H IgG fluorescence. P. aeruginosa (ATCC 27853) was added to the serum for 
absorption of non-S. maltophilia specific antibodies. For antigen preparation, reference 
strain ATCC 13637 was cultured overnight on blood agar plates at 35 °C. Colonies were 
harvested from the plate with 1 µL inoculation loop and resuspended in 1 mL 
PBS/Tween 20. The suspension was diluted 1:100 and aliquots of 10 µL were 
transferred to slide spots, which were air-dried. The slide was immersed on acetone for 
15 min. Slide was air-dried and stored at room temperature. For P. aeruginosa antibody 
absorption, four plates of reference strain ATCC 27853 were cultured at 37 °C for 24 h. 
Colonies were collected after adding 2.5 mL of NaCl 0.9 % (w/v) to each plate. A volume 
of 300 µL of formalin at final concentration of 1.0 % was then also added and incubated 
for 48 h at room temperature. This “Pyo suspension” was centrifuged for 5 min at 
5,000g. The pellet was washed three times (1:1) with NaCl 0.9 %. A total of 10 µL of 
serum was mixed with 100 µL of Pyo suspension (1:10 dilution) and 90µL of PBS/Tween 
20 and further incubated for 1 h at 37 °C. After incubation, this mixture was centrifuged 
for 10 min at 5,000 g and 20 µL of supernant was used for IFA (dilution 1:20). Serologic 
response was observed through immunofluorescence. The slide spots were each coated 
with 20 µL of sera diluted to varying degrees with the range 1:80 to 1:2,560, from the CF 
patients and healthy individuals, and incubated for 30 min at 37 °C in a humid chamber. 
Slide spots were washed with PBS/Tween 20 for 10 min and allowed to dry for 5 min at 
37 °C. A total of 20 µL of conjugate Fluoline H (1:500 dilution in PBS/Tween 20) was 
added to each spot and incubated for 30 min at 37 °C in a humid chamber. Slide-spots 
were washed in PBS/Tween 20 for 10 min at room temperature and then washed for 
10 s with distilled water. Excess liquid was removed by gently tapping the slide on filter 
paper. Whilst still moist, slides were mounted and examined under the microscope. 
Results were expressed as a quantitative antibody level (titre). To verify if there were 
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significant differences in the antibody titres between the groups, unpaired non-
parametric Mann Whitney test was used. Receiver operating characteristic (ROC) curve 
analyses were used to define optical cut-off titres through the highest sensitivity and 
specificity points (Kelly et al., 2008; Fan et al., 2006). Sensitivity and specificity values  
were calculated at 95.0 % confidence intervals (CI) using the Prism 5.0 software 
package (Graph Pad Software, San Diego, CA, USA). 
 
2.12 Antimicrobial effects of Epigallocatechin-3-gallate (EGCg), a natural 
compound of green tea as an alternative therapy 
2.12.1 Preparation of the antimicrobial agents 
EGCg and colistin (COL) were obtained from Sigma (Sigma-Aldrich, St Louis, 
MO, USA). Stock solutions (1,024 mg/L) of EGCg were freshly prepared and diluted in 
MHB containing 1.0 % (v/v) DMSO. COL stock solutions (2,048 mg/L) were also 
dissolved and diluted in MHB including 1.0 % DMSO. COL stock solution was stored at -
20 °C until use. For in vivo experiments, EGCg and COL were either only dissolved in 
PBS (wild type mice experiments) or sterile distilled aqua (Cftr mutant mice experiments) 
at room temperature.  
 
2.12.2 Microdilution assay 
Susceptibility testing was carried out according to the guidelines of the CLSI 
(CLSI, 2009). For the broth microtitre dilution tests, 96-well microtitre plates with 50 µL 
of between 0.5 to 1,024 mg/L EGCg per well were inoculated with 50 µL of MHB 
containing a bacterial cell suspension of between 1×105 to 5×105 colony-forming units 
per mL (CFUs/mL) of S. maltophilia. The plates were incubated for 24 h at 35 °C. MIC 
was determined as the lowest concentration able to inhibit visible growth. MBC was 
determined by transferring 10 µL aliquots of the cell suspensions that exhibited no signs 
of growth in broth microtitre dilution plates onto Columbia blood agar with 5.0 % (v/v) 
sheep blood. The inoculated plates were further incubated for 24 h at 35 °C. After 
incubation, MBC was defined as the lowest concentration that showed no growth. 
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2.12.3 Time-kill assay 
The kinetics of the bactericidal effect of EGCg on S. maltophilia was investigated 
using reference strain ATCC 13637 and two CF clinical isolates (obtained from an 
intermittent and a chronically colonised patient, respectively designated as Sm1 and 
Sm2) in a microtitre plate assay as previously described (Gordon and Wareham, 2010). 
The clinical isolates Sm1 and Sm2 were both chosen as their MIC’s and MBC’s (Table 
8) were representative for the collection of strains and they are both strong biofilm 
producers. Samples were cultured on blood agar plates and grown for 24 h at 35 °C. 
One glass tube per culture, containing 5 mL of TSB, was inoculated with a single colony 
and was incubated overnight in an orbital shaker at 35 °C with agitation at 145 rpm. A 
dilution of 1:10 was carried out (approximately 1×107 CFU/mL) and aliquots of 100 µL 
were placed in wells of a sterile flat-bottomed 96-well polystyrene microtitre plate 
(BRANDplates, BrandTech Scientific, Essex, CT, USA). The plates were incubated for 0, 
2.5, 5, 10, or 24 h at 35 °C. At the indicated time points, a mixture of 0.85 % saline 
supplemented with XTT and menadione (at final concentrations of 100 g/L and 10 g/L, 
respectively) was added and the plates were further incubated for 2 h in the dark at 
35 °C. A set of controls consisted of wells containing only TSB, TSB with inoculum and 
TSB with EGCg (tested concentrations). The reduction of XTT was used as a marker of 
cell viability. XTT reduction was measured colorimetrically at 492 nm. 
 
Table 8 Susceptibility of S. maltophilia isolates to COL and EGCg as determined by the 
reference microdilution method of the Clinical and Laboratory Standards Institute. 
Compounds 
 
ATCC 13637   Sm1   Sm2 
  
MIC MBC 
 
MIC MBC 
 
MIC MBC 
COL (mg/L) 
 
128 256 
 
256 256 
 
256 256 
EGCg (mg/L) 
 
8 32 
 
32 128 
 
32 64 
 
 
2.12.4 In vivo experiments 
Caenorhabditis elegans 
Caenorhabditis elegans var. Bristol strain N2 was used. 
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Mouse strains 
All mice were maintained in isolated cages to provide a pathogen-free environment at 
the Central Laboratory Animal Facility of the University Hospital Essen, Essen, 
Germany. Animal experiments were approved by the ethical committee of 
Landesumweltamt Nordrhein-Westfalen (Q1299/12), Germany. 
 
C57/BL6 
These mice were purchased from Harlan Winkelmann GmbH (Roosdorf, Germany). 
 
B6.192P2 (CF/3)-Cftr TgH (neoim)Hgu 
This Cftr mutant mouse strain is bred and housed at the University Hospital Essen, 
Essen, Germany. 
 
2.12.4.1 Cytotoxicity of EGCg on C. elegans 
All experiments were carried out using age-synchronised young adult animals. 
Synchronization was performed by bleaching gravid adults with lysis buffer as previously 
described (Stiergale, 2006) but with the following modifications. Eggs were plated onto 
lawns of Escherichia coli OP50 (food source) on NGM agar media, and allowed to hatch 
and develop into young adults at 25 °C (approximately 42 h after synchronisation). 
Synchronous population was collected and washed five times using M9 solution. Final 
concentrations of EGCg (256 mg/L; 512 mg/L; 1,024 mg/L and 2,048 mg/L) were added 
to the wells, as indicated. Control consisted of animals exposed only to NGM liquid. The 
nematodes were incubated for 48 h at 25 °C. Data is expressed as the average of two 
independent experiments performed in triplicate.     
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Figure 5 Representative standard curve of clinical isolate Sm1 for A600nm-CFU relationship for 
S. maltophilia (Sm1). 
2.12.4.2 Antimicrobial effects of EGCg on S. maltophilia during infection in C. 
elegans 
A C. elegans synchronised population was obtained as described above (2.13.4.1). To 
infect the nematodes, 20 mL of LB broth were inoculated with a single colony of 
S. maltophilia clinical isolate (Sm1) which was then incubated overnight in an orbital 
incubator 35 °C with agitation (150 rpm). Aliquots of 1 mL of inoculum adjusted to 
0.5 × 107 CFUs/mL were added to each well containing varying concentrations of EGCg 
(2×MIC= 512 g/L and 4×MIC= 1,024 g/L) diluted in NGM liquid. Control wells consisted 
of C. elegans containing 1 mL NGM and 1 mL of inoculum. A control set containing only 
NGM medium liquid and C. elegans was also used. The assays were carried out in 
duplicate of three independent experiments with approximately 20 worms per group. The 
experiments were assessed every 24 h for worm mortality on continuous exposure to 
pathogen and EGCg under the conditions described above. Worms were considered 
dead if they did not move or did not exhibit muscle tone. C. elegans survival was plotted 
using Kaplan-Meier survival curves and analysed by the log rank test using GraphPad 
Prism software. Curves resulting in P values < 0.05 relative to control were considered 
significantly different.  
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2.12.4.3 Inhalation effects of EGCg in vivo pulmonary infection 
Antimicrobial effects of EGCg were investigated in comparison to COL in female 
C57BL/6 specific-pathogen-free mice at age of 6 to 8 weeks. Two hours before infection, 
C57BL/6 mice were nebulised for 5 min with 1 mL of 1,024 mg/L EGCg (n=11), 
128 mg/L COL (n=12), and 1mL 1×PBS (n=13) using an inhalator (Pari Boy® SX, 
Starnberg). The outside of the mouthpiece of this device was sealed, leaving only a 
small orifice, in order to fit the mouse’s nose. Acute pulmonary infection was performed 
with clinical isolate Sm1. Bacteria from frozen stock were cultured on LB agar plates 
overnight and a suspension of these bacteria was adjusted to an OD of 0.225. Bacterial 
suspension was then cultured at 35 °C for 60 min with gentle agitation (125 rpm) to 
reach early logarithmic growth phase. Bacteria were washed with RPMI 1640 
supplemented with 25mM HEPES (pH 7.4). After definition of the OD (Figure 5), bacteria 
were resuspended at a density of 1 × 10 7 CFU/ 20µL in RPMI 1640. A solution of 
xylazine (10 mg/Kg) and ketamine (50 mg/Kg) prepared in sterile 1×PBS at final 
concentrations of 2 g/L and 10 g/L respectively, was used to anesthetise the mice. 
Intratracheal instillation was achieved using a 20-gauge needle with the assistance of a 
laryngoscope, allowing the delivery of 20 µL of the inoculum directly into the trachea 
(Rayamajhi et al., 2011). One hour post-infection, mice were induced to inhale EGCg, 
COL and PBS again under the same conditions detailed above. Clinical conditions of the 
mice were assessed as described previously (Lloyd and Wolfensohn, 1999). Mice were 
euthanized by cervical dislocation four hours after the infection. In order to release 
intracellular bacteria, the lungs of the mice were mechanically homogenised and lysed 
for 10 min in 5 g/L saponin with gentle shaking (125 rpm) at 35 °C and washed once in 
RPMI 1640 (HEPES 25mM, pH 7.4). Finally, dilutions of the homogenate lung tissues 
were cultured on LB agar plates in triplicate. Bacterial load from mouse lungs was 
determined after 18 h of growth at 35 °C. In Cftr mutant mice, both nebulisations (two 
hours prior infection and one hour post-infection) were performed with 1,024 mg/L EGCg 
(n=10) and sterile distilled water (n=10) as control. The infection in Cftr mutant mice was 
performed with 20 µL of bacterial suspension adjusted to 1 × 10 6 CFU. 
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2.12.5 Biofilm formation assay 
The biofilm assay was performed as previously described (Stepanović et al., 
2007) but with the following modifications. Overnight cultures of S. maltophilia in 5 mL 
TSB with an optical density 620 equivalent to 1 (OD620) (approximately 1×10
9 CFU/mL) 
were diluted to 1:10, and 100 µL of the diluted inoculum (approximately 1×107 CFU/mL) 
were transferred to the wells of a sterile flat-bottomed 96-well polystyrene microtitre 
plate (BRANDplates, BrandTech Scientific, Essex, CT, USA) and incubated for 24 h at 
35 °C. Nonadherent cells were subsequently removed by washing two times with 200 µL 
sterile distilled water. The amount of biofilm biomass was assessed by crystal violet 
staining. Biofilms were stained with 125 µL of 1.0 % (w/v) crystal violet for 20 min. The 
dye solution was discarded, and the plate was washed three times with sterile distilled 
water and allowed to air-dry for 24 h at room temperature. Stained biofilms were 
exposed to 30.0 % (v/v) acetic acid for 30 min, and the OD620 of the extracted dye was 
subsequently measured. 
 
2.12.6 Effects of EGCg and COL on biofilm formation 
The effects of EGCg and COL on S. maltophilia biofilm formation were 
determined as follows. First, biofilms were cultivated as described above (Pompilio et al., 
2011a; Stepanović et al., 2007). After 24 h incubation at 35 °C, the formed biofilms were 
washed twice with 200 µL of distilled water to remove nonadherent cells. TSB 
supplemented with EGCg or COL (Table 8) was added to wells containing biofilms and 
further incubated for 24 h at 35 °C. After the incubation period, biofilm biomass was 
assessed by crystal violet staining. Biofilms were washed twice with 200 µL of distilled 
water and stained with 125 µL of 1.0 % (w/v) crystal violet for 20 min. Dye solution was 
then removed and discarded, and plates were washed three times with sterile distilled 
water and allowed to air-dry in the dark for 24 h. A volume of 15 µL 30.0 % (v/v) acetic 
acid was added to stained biofilms and incubated for 30 min at room temperature. The 
OD620 of the extracted dye was subsequently measured. 
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2.12.7 Effects of EGCg and COL on young and mature S. maltophilia biofilms 
To evaluate the disruptive effects of EGCg, we cultivated Sm biofilms 
(ATCC13637, Sm1 and Sm2) in a 96-well microtitre plate assay (Pompilio et al., 2011b; 
Xu et al., 2011). Tubes with 10 mL TSB were cultivated with a single colony from each 
tested sample. Aliquots of 100 µL from 1:10 dilution of the overnight cultures 
(approximately 1×107 CFU/mL) were transferred to the wells of sterile flat-bottomed 96-
well polystyrene microtitre plates. The plates were incubated for 24 h at 35 °C. The 24-
h-old biofilms were treated with 100 µL of EGCg at 0.25×MIC, 0.5×MIC, or 1×MIC (Table 
8) and were incubated at 35 °C for an additional 24 h. After incubation, the culture 
medium (TSB with EGCg or COL) was removed, and the treated biofilms were washed 
two times with sterile distilled water. Seven-day-old biofilms were cultivated in parallel. 
These biofilms were washed with sterile distilled water every 24 h during the incubation-
period, and the medium was supplemented with new TSB. After the maturation period, 
7-day-old biofilms were treated in the same manner as 24-h-old biofilms. To determine 
the metabolic activity of the biofilms, we added 100 µL aliquots of saline solution XTT 
(100 g/L) and menadione (10 g/L). The plates were incubated in the dark for 2 h at 
35 °C, and the absorbance was measured at 492 nm. The in vitro effect of EGCg on the 
viability of S. maltophilia biofilm was plotted as the ratio of viability (cells with active 
metabolism) in treated samples to viability in untreated samples. Control wells contained 
TSB without EGCg. The in vitro effect of EGCg on the viability of S. maltophlia biofilm 
was plotted as the ratio of viability (cells with active metabolism) in treated samples to 
viability in untreated samples. The effects of COL on young and mature biofilms were 
determined as described for EGCg. 
 
2.12.8 Confocal laser scanning microscopy of S. maltophilia biofilms 
Qualitative and quantitative microscopic evaluations of the biofilms were carried 
out through a combination of LIVE/DEAD BacLight viability staining and automated 
confocal laser scanning microscopy (CLSM), as previously described (Müsken et al., 
2010). A single colony of each sample was inoculated into individual tubes containing 
2 mL of LB medium and incubated in an orbital shaker for approximately 16 h at 35 °C 
with agitation (180 rpm). Overnight cultures were diluted with fresh LB broth to an OD600 
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of 0.02 (1× 109 CFU/mL), and 100 µL aliquots from these dilutions were transferred to 
the wells and covered with air-permeable cover foil. The plates were incubated for 24 h 
at 35 °C in an incubator with humidified atmosphere. The 48-h-old biofilms of strains 
ATCC 16367, Sm1, and Sm2 were visualised after 24 h exposure to COL or EGCg at 
various concentrations. For this assay, the DNA-binding dyes Syto9 (green) and 
propidium iodide (PI; red) were used. This two-colour kit differentially stains living 
(green) and membrane-compromised/dead (red) bacteria according to differences in 
membrane permeability. After addition of COL or EGCg, 20 µL of a staining solution 
containing Syto9 and PI (at final concentrations of 1.4 µM and 8.3 µM, respectively) was 
added to each well.  Biofilm susceptibility to either COL or EGCg was determined on the 
basis of the fractions of red (including co-localized) and green biovolume (µm3) 
calculated from the image stacks with a custom-designed algorithm in the software 
Developer XD (Definiens). Syto9 was excited with a 488 nm wavelength laser and 
detected with a 540/75 nm band-pass emission filter, whereas PI was excited at 561 nm 
and detected with 600/40 band-pass emission filter. The negative controls were biofilms 
treated with LB broth supplemented with 1.0 % (v/v) DMSO, and the positive control 
(killing biofilm control) were treated with formalin at final concentration of 1.0 % (v/v). 
Visualisation of biofilm sections was performed with the software IMARIS version 5.7.2 
(Bitplane, South Windsor, USA). Data are expressed as means of two independent 
experiments. Experiments were carried out in duplicate. 
 
2.12.9 Statistical analysis 
All assays were performed in triplicate, and the results are shown as 
means ± SDs. A one-way analysis of variance (ANOVA), followed by the Dunnett test, 
was used to detect differences in efficacy against biofilm formation (spectrophotometric 
OD readings) and biovolume/bioviability of young and mature biofilms between isolates 
exposed to EGCg or COL for 24 h. The Mann-Whitney U test was used to address the 
differences among bacterial counts in mice nebulised with EGCg, COL, PBS and aqua. 
Significance was set at P <0.05. 
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3 Results 
3.1 Improved detection and susceptibility testing of S. maltophilia isolates 
3.1.1 Steno medium agar (SMA) improved the isolation of S. maltophilia from 
sputum samples  
A comparative investigation of a novel selective medium (SMA) with conventional media 
for the detection of S. maltophilia was carried out. Out of 623 sputum samples from 165 
CF patients, conventional media revealed that yeasts (52.4 %), Pseudomonas spp. 
(52.0 %), Staphylococcus aureus (48.3 %) and Aspergillus spp. (31.7 %) were the most 
frequent isolated microorganisms. The frequency of the most isolated microbes in 
relation to all samples analysed is shown in Figure 6.  
 
Figure 6 Isolation frequency of microorganisms using conventional media from 623 sputa from 165 
CF patients. 
 
A total of 72 sputum samples from 33 CF patients aged 1 to 51 years revealed the 
presence of S. maltophilia. It was observed that conventional media supported the 
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growth of this pathogen in 7.1 % of the sputum samples examined. Interestingly, the 
detection rate of this pathogen increased to 11.6 % when a selective medium was used, 
indicating that SMA supported the growth of 64.0 % more S. maltophilia isolates than 
conventional media. There was no case in which the conventional media allowed 
detection of S. maltophilia and SMA did not. Usually, S. maltophilia was isolated alone, 
as well as with other accompanying facultative pathogenic species, such as Aspergillus 
fumigatus (30.6 %), Candida albicans (46.3 %) and P. aeruginosa (39.6 %). Patient 
demographics related to the detection of Aspergillus spp., Pseudomonas spp., and 
S. maltophilia are shown in Table 9. Contrary to Aspergillus spp. and Pseudomonas 
spp., S. maltophilia was more frequently isolated from female than from male patients.   
 
Table 9 Demographic characteristics of 165 CF patients according to clinical relevance 
interest of species isolation 
Patient features Aspergillus spp. Pseudomonas spp. S. maltophilia 
Mean age ±SD 
(range) 
24.1±6.5 
(1-51) 
27.4±8.2 
(5-79) 
22.2±8.8 
(1-51) 
Female (%) 36.6 39.5 57.5 
Total (n) 71 91 33 
SD= standard deviation 
 
3.1.2 Tygecycline and trimethoprim-sulfamethoxazole demonstrated the best in 
vitro inhibitory activity against S. maltophilia isolates 
The MICs at which 50 % (MIC50) and 90 % (MIC90) of S. maltophilia isolates were 
inhibited by various antibiotics and the percentages of susceptible and resistant isolates, 
according to established breakpoints, are presented in Table 10. Tigecycline and 
trimethoprim-sulfamethoxazole, amongst all tested agents, revealed the highest in vitro 
activity against S. maltophilia (98-100.0 % susceptibility), followed by quinolones 
(levofloxacin and moxifloxacin) and fosfomycin (89-92.0 % susceptibility). Conversely, 
colistin, ceftazidime, and ticarcillin-clavulanate acid exhibited limited in vitro activity (44-
64.0 % susceptibility).   
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Table 10 In vitro activity of eight antimicrobial agents tested against S. maltophilia by Etest. 
MIC= minimum inhibitory concentration. MICs at which 50 (MIC50) and 90 % (MIC90) of S. maltophilia isolates were inhibited.  
Antimicrobial agent 
                        
  MIC (µg/mL) % (n=65) of strains 
  Range (µg/mL) 50 % of strains 90 % of strains Susceptible Intermediate Resistant 
Ceftazidimine 0.016-256 3 32 63.0 7.6 29.4 
Colistin 0.016-256 3 12 44.6 26.1 29.3 
Fosfomycin 0.016-256 6 12 92.3 - 7.7 
Levofloxacin 0.002-32 0.625 2 92.3 - 7.7 
Moxifloxacin 0.002-32 0.25 1 89.5 7.5 3.0 
Ticarcillin-clavulanate acid  0.016-256 4 32 64.1 16.4 19.5 
Tigecycline 0.016-256 0.094 0.218 98.4 - 1.6 
Trimethoprim-sulfamethoxazole 0.002-32 0.38 1 100 - - 
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3.2 Genotyping methods reveal that S. maltophilia strains are highly diverse 
Analysis of bacterial pathogens using various typing methods is essential for 
investigating strains relatedness, tracing geographic dissemination of bacterial clones 
(cross-transmission), as well as for long-term epidemiological studies (Struelens, 1996). 
Therefore, molecular analyses of S. maltophilia isolates from different sources (sputa 
from CF and ICU patients; and environment) were performed using the semi-automated 
rep-PCR Diversilab (DL) system (n=102) and ERIC-PCR (n=97).  
The DL system was able to type most of the isolates, except for two clinical CF samples. 
By using a similarity cut-off of 95 %, DL typing revealed great heterogenicity by 
distinguishing 100 isolates into 70 DL types, of which 30 were considered singletons or 
unique patterns. The other clusters represented clonally related isolates compromising 
two or more isolates. The largest clonally related group was composed of six isolates.  
ERIC-PCR also successfully typed all isolates, with a few exceptions that did not exhibit 
band pattern (n=6; 2 from CF and 4 from ICU patients, respectively). Cluster analysis 
revealed the presence of eight different profiles. The dendrogram derived from ERIC-
PCR is illustrated in Figure 3.2. Among them, four groups were strictly composed of 
isolates from CF patients (groups A, B, C and D), whereas one group was formed only 
by isolates obtained from ICU individuals (group E). The other three clusters contained a 
mixture of isolate types/origins. 
Interestingly, statistical analyses showed that DL and ERIC-PCR provided relatively high 
resolution power with SID values of 0.990 (95 % CI; 0.983 to 0.996) and 0.869 (95 % CI, 
0.851 to 0.888), respectively. Clustering analyses of both typing methods revealed a lot 
of related and distinct genotypes. Overall, AR and W coefficient values (<0.5) 
demonstrated a weak correlation between the information provided by DL and ERIC-
PCR methods.  
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Figure 7 Dendrograms of S. maltophilia based on the genomic fingerprints generated by ERIC-
PCR. Genetic similarity among samples isolated from CF, ICU and environment were estimated by Ward 
algorithm. 
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3.3 S. maltophilia CF isolates demonstrated a higher content of fatty acids in 
comparison to environmental and ICU isolates  
Environmental and physiological factors are known to affect the fatty acid composition of 
bacteria. For that reason, the relationship between the fatty acid profiles of S. maltophilia 
isolates from CF and ICU patients, and also from the environment, was investigated by 
Microcrobial Identification System (MIS) 2-D plot. The clustering analysis revealed no 
grouping corresponding to CF, ICU or environmental isolate types (Figure 8). However, 
clustering was observed within “CF chronic colonised” and “CF non chronic colonised” 
groups.  
Further, the peak area index (PAI), which provides information about the amount of fatty 
acids present in the broth culture during bacterial growth, was investigated. Isolates of 
S. maltophilia from CF patients, ICU patients and the environment showed mean PAI 
values of 12.7 (range 4.0-98.8), 9.2 (range 7.2-12.6) and 7.4 (range 5.4-11.2). 
Surprisingly, specimens from CF patients revealed significantly higher amounts of fatty 
acids in comparison to samples from ICU patients and the environment. There was also 
a significant difference in the amount of fatty acids between the ICU patient samples and 
environment samples (Figure 9).  
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Figure 8 MIS 2-D plot cluster analysis of FAME profiles from S. maltophilia isolated from different 
sources (CF patients=C; ICU patients= I; environmental= E). Group A: S. maltophilia isolates from CF 
patients initially colonised with this bacterium (non-chronic colonised). Group B: S. maltophilia isolates 
from CF patients chronically colonised with this pathogen.  
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Figure 9 Peak area index of S. maltophilia isolates from cystic fibrosis (CF) patients, intensive care 
unit (ICU) patients and from the environment. *P<0.05; **P<0.01; ***P<0.0001. 
 
3.4 MALDI-TOF mass spectra revealed that S. maltophilia isolates from CF 
patients are clustered together 
Principal component analysis (PCA), based on MALDI-TOF mass spectra, was carried 
out in an attempt to differentiate S. maltophilia isolates based on their origin (CF and 
ICU patients, and environment). Figure 10 shows the score plot of the first three 
principal components on a set of mass spectra obtained from 100 S. maltophilia 
isolates. In this plot, S. maltophilia isolates obtained from CF patients could be identified 
as a distinct group, whereas ICU and environmental samples grouped in a mixed 
manner.   
The dendrogram generated by the hierarchical cluster analysis, based on the peak lists 
derived from MALDI-TOF mass spectra, revealed the presence of five distinct groups (A, 
B, C, D and E) (Figure 11). Clusters B and D were strictly composed of samples isolated 
from CF patients.  
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Figure 10 Principal component analysis of 100 S. maltophilia isolates obtained from CF and ICU patients and from the environment. 
CF, ICU, environmental and ATCC 13637 isolates are respectively represented by the colours red, green, gray and blue.   
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Figure 11 Dendrogram of 100 S. maltophilia isolates obtained from CF and ICU patients and from the environment. Distances are 
displayed in relative units. 
3 Results 
 
 
58 
A visual comparison of averaged mass spectra of CF isolates in comparison to those of ICU 
or environmental samples did not show any remarkable difference (Figure 12). Taking this 
into consideration, this fact emphasizes the necessity to conduct more complex analyses, 
such as hierarchical cluster analysis and PCA.  
 
Figure 12 Averaged MALDI-TOF mass spectra of S. maltophilia samples. A) Comparison between averaged 
MALDI-TOF mass spectra of CF (red) and environmental (green) S. maltophilia samples. B) Comparison 
between averaged mass spectra of CF samples (red) and ICU (green) S. maltophilia isolates. r. int. = relative 
intensity. 
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3.5 Chronic S. maltophilia infection in CF patients is associated with a specific 
immune response  
S. maltophilia antibody titres were measured in 100 sera samples from 64 CF patients 
and 36 healthy individuals by quantitative immunofluorescence assay. Data 
demonstrated that 28 (43.7 %) out of the 64 patients had chronic “S. maltophilia” 
colonisation, 10 (15.7 %) had intermittent “S. maltophilia” colonisation and 11 (17.2 %) 
never had either S. maltophilia or P. aeruginosa isolated from their respiratory tract. It 
was also observed that 15 (23.4 %) of CF patients were chronically colonised with P. 
aeruginosa but never with S. maltophilia. Baseline characteristics of the CF patients are 
summarised in Table 11.  
The relationship between antibody titres and forced expiratory volume in 1 s (FEV1) was 
examined. A significant inverse correlation between the mean S. maltophilia antibody 
titres and FEV1 percent prediction was observed (R square=0.2106; P=0.0013) (Figure 
13). Therefore, it is plausible to assume that CF patients with high antibody titres 
consequently tend to exhibit high FEV1 values. In this particular case, due to the limited 
number of patients, multivariate regression analysis was not performed to address the 
associations between S. maltophilia antibody titre and markers of clinical outcome.    
 
 
Figure 13 Mean S. maltophilia antibody titres and corresponding FEV1 percent predicted. Each dot 
represents a single patient. Sm= S. maltophilia. 
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Table 11 Demographic and clinical data regarding healthy subjects and CF patient groups. 
Characteristic Healthy (n=36) 
Never Sm/Pa 
(n=11) 
Intermittent Sm 
(n=10) 
Chronic Sm 
(n=28) 
Chronic Pa never 
Sm (n=15) 
Sm antibody titre 
(geometric mean) 0.91 7.3 22.6 320.1 30.5 
Age, mean (SD) 31.9 (±9.7) 14.0 (±7.9) 20.0 (±10.1) 21.2 (±8.9) 26.0 (±7.2) 
Sex (male) 18 (50%) 9 (81.9%) 5  (50%) 13 (46%) 6 (40%) 
Mutation 
dF580/dF580 - 18.10% 60% 50% 73.30% 
Pancreatic 
insufficiency - 90.90% 100% 75% 93.30% 
CFDR - 0% 20% 10.70% 33.30% 
BMI (range) - 18.1 (14.1-22.3) 19.3 (15.1-23.4) 18.0 (14.5-23.8) 19.8 (16.2-30.4) 
FEV1 mean 
(range) - 84.7 (35-111) 61.7 (40-94) 55.7 (28-108) 56.4 (16-116) 
Pseudomonas 
aeruginosa positive - 0.00% 90% 50% 100% 
Burkolderia 
cepacia positive - 0% 0% 0% 0% 
Aspergillus positive - 18.10% 80% 53.50% 86.70% 
Lung transplant - 0% 0% 0% 6.70% 
 
Definitions of abbreviations: Sm= Stenotrophomonas maltophilia; BMI= body mass index; CFDR=cystic fibrosis-related diabetes; FEV1= forced 
expiratory volume in 1 second. 
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S. maltophilia antibody titres were substantially different between the three groups of CF 
patients, except for between “never S. maltophilia/P. aeruginosa” and “intermittent 
S. maltophilia” groups (P=0.2688) (Figure 14). Patients with “chronic S. maltophilia” 
exhibited significantly higher S. maltophilia antibody titres in comparison to healthy 
individuals (P<0.0001), CF patients with “intermittent” (P=0.0315) and “never 
S. maltophilia/P. aeruginosa” (P=0.0002). No evidence of S. maltophilia antibodies 
cross-reactivity to P. aeruginosa was found due to the fact that S. maltophilia antibody 
titres in patients “never S.maltophilia/P. aeruginosa” and “never S. maltophilia but 
chronic P. aeruginosa” were not significantly different from each other (P=0.1898) 
(Figure 14).  
 
 
 
 
 
 
 
 
 
 
Figure 14 Antibody levels of S. maltophilia. A) Antibody levels of S. maltophilia (Sm) whole cell in 
serum samples from healthy subjects (healthy), CF patients with chronic (CF chronic Sm), intermittent (CF 
intermittent Sm), and never Sm without P. aeruginosa (CF never Sm/Pa). Antibody levels are reported as 
titres. P values <0.0005 by non-parametric test were considered significantly different. B) Comparison of 
antibody titre between CF “never Sm/Pa” and CF “never Sm but chronic Pa”. Antibody titres did not differ 
between the groups (P=0.1898).   
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Figure 15 illustrates the ROC curve analysis used to identify CF S. maltophilia 
chronically colonised patients according to titre value. The area under the receiver 
operating characteristic curve (AUC), a measurement known as the discriminatory 
power of the diagnostic test, was 0.88 (95 % CI: 0.59-0.91). The titre value of >1:120 
was considered the best cut-off, since it has provided both the highest sensitivity and 
specificity to distinguish between CF “never S.maltophilia/P.aeruginosa” and CF “chronic 
S. maltophilia”.  Based on that, sensitivity, specificity, positive predictive value (PPV) 
and negative predictive value (NPV) were 78.5 %, 81.8 %, 70.7 % and 84.7 %, 
respectively.  
 
    
 
 
 
 
 
 
Figure 15 Receiver operating curve (ROC) for IFA detecting serum antibodies against S. maltophila 
(Sm) whole cell. ROC data (AUC value=0.8815; standard error=0.052; P=0.0002) of CF patients never 
colonised S.maltophilia/P.aeruginosa (Sm/Pa) versus CF patients with chronic S. maltophilia.  
 
3.6 Long-term adaptation of S. maltophilia bacterial population in the CF lung: 
high molecular diversity, hypermutation and antibiotic resistance 
To expand the undergoing of the matter of S. maltophilia adaptation to the CF airway, 
we examined the genotypic diversity, mutation frequency and antibiotic resistance of 
S. maltophilia isolates from chronically colonised CF patients. Our long-term S. 
maltophilia sputa collection, over a period of four years, consisted of a total of 90 
isolates obtained from 19 CF patients classified as chronically colonised (Waters et al., 
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2011). An average of 4.8 (±3.3) sputum samples per patient was analysed. Most of the 
CF patients were females (52.6 %) and the mean age for the onset of chronic 
colonisation with S. maltophilia was 25 years (±12.8). There was no correlation between 
the mean number of sputa samples collected per patient and the type of mutation in the 
CFTR gene. 
To evaluate the possibility of CF S. maltophilia populations being a consequence of a 
single (or few) clones’ dissemination, these bacterial isolates were fingerprinted using 
the semi-automated, rep-PCR method (DiversiLab® system). Demographic and 
genotypic characteristics of the CF patients, as well as the genotype features related to 
the S. maltophilia isolates obtained from these patients are summarised in Table 12. 
Genotyping of the consecutive clinical isolates revealed the existence of 38 genotypes. 
In addition, a total of 13 (68.4 %) of the CF patients, during the course of the study, 
harboured diverse S. maltophilia genotypes. Patient 3, for example, was the one that 
harboured the most different genotypes (n=8) within 34 months (Figure 16). Patients 7, 
10 and 11 presented three genotypes, while patients 8, 9, 13, 14, 15, and 17 presented 
only two. It was also noted that 31.6 % (n=6) of these patients were colonised with 
unique clones (Table 12). Interestingly, data also showed that certain S. maltophilia 
genotypes were shared by 10 patients (1, 3, 4, 7, 10, 11, 13, 15, 16 and 17). 
In order to exclude confounding factors that could alter the rep-PCR banding patterns 
due to culture age and/or clonal expansion during growth of multiple subcultures, rep-
PCR pattern stability was examined. At three different time points (1, 5 and 10 days), 
three distinguishable colonies from a clinical CF isolate were collected and rep-PCR was 
carried out. Through this approach, it was possible to demonstrate that S. maltophilia 
genotype was subculture stable and rep-PCR was also able to give reproducible results 
(Figure 17). 
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Table 12 Demographic and genotypic characteristics of 90 S. maltophilia isolates obtained from 19 CF patients. 
Patient Sex Age (years) CF mutation No. of sputa Genotypes 
Patient 1 F 17 dF508/R553X 9 1,8,9,22,32 
Patient 2 M 12 dF508/dF508 2 30 
Patient 3 F 11 dF508/dF508 15 11,12,13,14,16,21,23,37 
Patient 4 F 28 dF508/327-26-A>G 10 10,13,14,16 
Patient 5 M 27 dF508/dF508 5 34 
Patient 6 M 24 dF508/dF508 2 6 
Patient 7 F 21 not identified 7 1,2,28 
Patient 8 F 36 not identified 3 24,25 
Patient 9 F 27 R347P/G542X 3 5,38 
Patient 10 M 21 dF508/R31C 4 13,14,15 
Patient 11 M 18 dF508/R553X 3 3,20,33 
Patient 12 F 12 dF508/dF508 2 29 
Patient 13 M 27 G1069R/3007delG 3 18,19 
Patient 14 M 20 dF508/dF508 6 26,36 
Patient 15 M 19 dF508/dF508 2 11,27 
Patient 16 F 14 not identified 6 17,18,27,31,33 
Patient 17 M 47 dF508/2789+5G>A 4 18,28 
Patient 18 F 65 dF508/- 3 35 
Patient 19 F 31 dF508/dF508 2 4 
The numbers in bold refer to the genotypes which are shared by different patients. 
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Figure 16 Molecular epidemiology of S. maltophilia samples isolated from patient 3. Dendrogram, 
virtual gel and the similarity matrix generated by the DL software. The gel-like image and similarity matrix 
exhibit the presence of eight different genotypes. 
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Figure 17 Assessment of subculture stability and reproducibility of rep-PCR. S. maltophilia was 
cultivated for 1, 5 and 10 days (indicated by the first number) and colonies from three sites 
(indicated by the second number) were investigated by rep-PCR. The horizontal bar at the bottom left 
shows the percent similarity coefficient of these samples. Subculture stability and reproducibility of 
S. maltophilia are shown by a high index of similarity (>98 %).   
 
Strong diversification over time and emergence of spontaneous mutator phenotypes can 
occur in bacterial populations colonising CF airways, since they are constantly exposed 
to a challenging environment and repeated antibiotic therapies (Tenaillon et al., 1999). 
The presence of mutators in CF patients chronically colonised by different bacteria have 
been supported by other studies (Román et al., 2004; Prunier et al., 2003; Oliver et al., 
2000). For that reason, mutator status of S. maltophilia isolates obtained from CF 
chronically colonised patients were examined. Estimation of the mutation frequencies 
revealed that 31.2 % (n=28) were strong mutators, 23.3 % (n=21) weak mutators, 
27.7 % (n=25) normomutators and 17.8 % (n=16) hypomutators. Approximately 58.0 % 
(n=11) of these patients harboured at least one strong mutator strain, whereas about 
37.0 % (n=7) of them harboured at least one hypomutator strain. Interestingly, it was 
noted that mutation rates of the most clonally related genotypes varied over time (Figure 
18) with a tendency to become a weaker mutator, except for genotype 1.    
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Figure 18 Mutation status of the genotypes clonally related and shared among different CF 
patients over time. Each black dot represents a single isolate obtained from a patient. The black line 
links the isolates that share the same genotype pattern according to rep-PCR.  The similarity among 
isolates was established as ≥95 % according to Pearson correlation index. 
 
It has been shown by other studies that mutator P. aeruginosa isolates obtained from 
chronically colonised CF patients tend to be more resistant to antibiotics than 
nonmutators (Ciofu et al., 2005; Oliver et al., 2000). To verify the impact of high 
prevalence of mutator strains on antibiotic resistance, susceptibility testing for nine 
antimicrobial agents was conducted (Table 13). Similarly as demonstrated for a different 
sputa collection, tigecycline and trimethoprim-sulfamethoxazole also exhibited the best 
inhibitory activity against S. maltophilia isolates obtained from chronically colonised CF 
patients. However, mutator isolates were neither found to be more resistant nor showed 
significantly higher MICs than non-mutator isolates for all antibiotics tested. 
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Table 13 Comparison of MICs for different antimicrobial agents tested against S. maltophilia isolates with nonmutator and 
mutator phenotypesa 
Antibiotic 
Nonmutator isolates (n=41) Mutator isolates (n=49) 
Statistical significance (P)c No. (%) resistant Mean MICb No. (%) resistant Mean MICb 
Ceftazidime 63.4 26.5 46.9 18.6 0.1402 
Colistin 56.0 6.8 59.1 7.3 0.8319 
Co-trimoxazole 14.6 0.3 18.3 0.3 0.5634 
Fosfomycin 60.9 37.2 67.3 51 0.6589 
Levofloxacin 24.3 1.1 32.5 1.3 0.4855 
Moxifloxacin 26.8 0.6 32.5 1 0.6463 
Tigecycline 2.4 1 4.0 1.5 1.0000 
Tobramycin 82.9 82.8 87.7 78.3 0.5593 
 
 a
 Non-mutator isolates (hypomutator and normomutator) included isolates with frequencies of ≤ 8 × 10
-9 
and 8 × 10
-9
< f < 4× 10
-8
; whereas 
rmutator isolates (weak hypermutator and strong hypermutator) had a frequency of 4 × 10
-8
< f < 4× 10
-7
 and ≥ 4 × 10
-7
. 
b
 Geometric mean of the 
MIC in mg/L. 
c
 P values (Fisher’s test) resulting from comparison of the MICs among non-mutator and mutator isolates. 
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3.7 EGCg, the main component of green tea, displays antibacterial and anti-biofilm 
properties against S. maltophilia  
In vitro characterisation of antibacterial effects of EGCg was carried out against 60 CF 
S. maltophilia isolates. EGCg was shown to be effective in inhibiting the growth of all 
tested isolates. The MIC values ranged from 64 to 512 mg/L, whereas MBC values 
ranged from 64 to 1024 mg/L (Figure 19).  
 
Figure 19 Distribution of minimum inhibitory concentration and minimum bactericidal 
concentration values determined by microdilution broth assay. Values are expressed as percentage 
of data obtained from 60 CF S. maltophilia isolates against EGCg. MIC= minimum inhibitory 
concentration; MBC= minimum bactericidal concentration. 
 
The MIC50/90 and the MBC50/90 for EGCG was 256 mg/L in all four cases. Time-killing 
curve data shows that EGCg, through a 24 h incubation period, was bactericidal against 
reference strain ATCC 13637, Sm1 and Sm2 at 2×MIC and 4×MIC (Figure 20).   
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Figure 20 Kinetics of the killing effect of EGCg on S. maltophilia ATCC 13637 and two clinical isolates. The concentrations of EGCg ranged 
from 0.5×MIC to 4×MIC. Bacterial viability over a 24 h period was determined by measurement of optical density (OD) at 492 nm visualised 
through XTT conversion. Control samples consisted of bacterial cells grown in tryptic soy broth (TSB) in the absence of EGCg. Experiments were 
designed in three independent sets performed in octuplicate, and the results are expressed as means ± standard deviation (SD).  
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Given the positive in vitro antimicrobial effects of EGCg against S. maltophilia, an in vivo 
toxicity assay was conducted to determine if diverse doses of EGCg would be lethal 
against uninfected nematodes. It was observed that after 48 h exposition to 256, 512 
and 1,024 mg/L of EGCg no significant lethal effects on C. elegans were observed 
(Figure 21). A complete mortality assay of C. elegans infected with Sm 1 was carried out 
over a period of five days (Figure 22). Nematodes infected with S. maltophilia and, 
subsequently, exposed to 1,024 mg/L of EGCg displayed enhanced survival up to a rate 
of 57.0 %, which was not considered significantly different from the control survival rate 
(P>0.05). Nematodes from the grows “only infected” and “infected/treated with EGCg 
(512 mg/L)” showed a survival rate to the level of 37.0% and 47.0%, respectively, which 
was considered statistically different from the control group (P=0.0002 and P=0.0059, 
respectively). Approximately 45.0% of the animals from the groups “infected/treated” 
with COL (64mg/L and 128mg/L) and “infected only” survived, suggesting a significant 
difference in the survival rate between control and these groups (P=0.0002 for all of 
them).  
 
 
 
 
 
 
 
 
Figure 21 Percentage mortality of wild-type C. elegans exposed during 48 h to diverse 
concentrations of EGCg (256, 512 and 1,024 mg/L). Data express the mean values of two independent 
experiments performed in triplicated, SDs are shown.  
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Figure 22 EGCg enhances the survival of C. elegans infected with S. maltophilia clinical isolate (Sm1). Results are shown as mean values 
of three independent experiments performed in triplicated, SDs are shown.  
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In order to study whether EGCg could be useful as a novel natural compound for the 
treatment (prophylactic and therapeutic) of acute S. maltophilia pulmonary infection in 
comparison to COL, three groups composed of wild type mice were treated either with EGCg, 
COL or placebo (1×PBS) (Figure 23A).  Mice were euthanised before their overall fitness was 
considered severe. A treatment regimen of nebulised EGCg significantly reduced the number 
of CFU/mL of S. maltophilia (P=0.0127) when compared with the untreated, but infected, and 
COL-treated (P=0.0106) groups. Infected mice which were nebulised with COL did not exhibit 
significantly reduced numbers of bacteria in the lungs in relation to the control individuals 
(P=0.4964). Remarkably, the data were similar to those obtained for nematode experiments. 
Therefore, these results encouraged us to investigate if EGCg would also affect the bacterial 
loads in Cftr mutant mice during S. maltophilia acute pulmonary infection. Bacterial counts in 
the lungs of the Cftr mutant mice nebulised with EGCg was significantly lower (P=0.0039) 
than in those nebulised with sterile distilled water (Figure 23B). 
 
Figure 23 Bacterial load after intratracheal instillation of S. maltophilia in C57BL/6 and Cftr mutant mice. 
A) Bacterial count in the lungs of C57BL/6 mice after infection with Sm1 nebulised (2 h before infection and 1 h 
post-infection) with 1×PBS (n=13), COL (n=12) and EGCg (n=11). Mice nebulised with EGCg exhibited 
significantly lower bacterial count (P=0.0127) in comparison to non-treated group (1×PBS).  Shown are mean ± 
SD and the distribution of the values. B) Bacterial count in the lungs of Cftr mutant mice after infection with Sm1 
nebulised (2 h before infection and 1 h post-infection) with aqua (n=10) and EGCg (n=10). Mice nebulised with 
EGCg exhibited significantly lower bacterial count (P=0.0039) in comparison to the non-treated group (aqua). 
Displayed are means ±SD and individual values. Aqua= sterile distilled water.  
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Eradication of S. maltophilia colonisation/infection in CF patients is often problematic 
due to S. maltophilia’s inherent resistance to antibiotics and also due to its ability to form 
biofilm. Therefore, the ability of the studied isolates to form biofilm was investigated. 
Only 10.0% of the CF S. maltophilia isolates did not produce biofilms, while the majority 
(90.0 %) were able to adhere and to form biofilms. The isolates were classified as weak 
(11.7 %), moderate (15.0 %), or strong (63.3 %) biofilm producers. The reference strain 
(ATCC 13637) and the tested clinical isolates (Sm1 and Sm2) were considered strong 
biofilm producers. 
Although subinhibitory concentrations (sub-MICs) of antimicrobial agents might not be 
able to kill bacteria, they could actually be able to modify their physical-chemical 
features, the architecture of the outermost surfaces and interfere with some of their 
functions (Davies and Spielman, 2006). Taking this into account, subinhibitory 
concentrations of COL and EGCg were employed to ascertain if they could also affect 
the biofilm development of the three tested strains in the growth medium TSB (Figure 
24) in comparison to the positive controls (untreated). Biofilms (ATCC13637, Sm1 and 
Sm2) treated with COL and EGCg displayed a significant biofilm growth reduction. 
ANOVA analyses demonstrated significant reduction of biomass in all isolates, 
suggesting that COL and EGCg exert anti-biofilm forming effects even at subinhibitory 
concentrations. 
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Figure 24 Effects of COL and EGCg against S. maltophilia biofilm formation. Reference strain 
ATCC13637 and two clinical isolates (Sm1, and Sm2) were used. Biofilms were stained with crystal 
violet and their biomasses were determined by optical density (OD) measurement at 620 nm. Compared 
to untreated control cells, samples exposed to EGCg and COL exhibited a significant reduction in the 
number of S. maltophilia sessile cells of ATCC13637 and Sm1. Results are expressed as average OD ± 
SD. Experiments were performed in triplicate. *P<0.05; **P<0.01; ***P<0.0001. 
 
Biofilms are thought to play a key role in bacterial persistence during chronic infections 
in CF patients. Therefore, in vitro dynamics of S. maltophilia biofilms when treated with 
COL and EGCg were assessed. As illustrated in Figure 25, after exposure to COL or 
EGCg for 24 h, metabolic activity of young (24-h-old) and mature (7-day-old) biofilm 
cells produced by tested samples (ATCC13637, Sm1 and Sm2) showed a mean 
decrease viability in comparison to untreated biofilms. COL showed significant inhibitory 
effects against young biofilm cells of all tested samples, but only Sm1 mature biofilm 
cells were significantly inhibited. EGCg significantly reduced the metabolic activity of 
ATCC13637 and Sm2 young biofilm cells. On the other hand, only mature biofilm cells 
of ATCC13637 were significantly reduced when treated with EGCg. Remarkably, the 
relative effects of COL and EGCg on the viability of mature biofilms were not considered 
dose-dependent.  
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Figure 25 Effects of COL and EGCg on 24-h- and 7-day-old established biofilms of S. maltophilia. Reference strain ATCC13637 and clinical 
isolates (Sm1 and Sm2) had their biofilm metabolic activity defined by XTT viability assay. OD measurement was determined at 492 nm, and 
results are expressed as average OD ± SD. Experiments were performed in triplicate. *P<0.05; **P<0.01; ***P<0.0001. 
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To verify the effects of COL and EGCg on morphology and viability of the biofilms 
produced by CF strains of S. maltophilia, we performed CLSM on 48-h-old biofilms 
produced by the tested samples. Figure 26 illustrates representative biofilm sections of 
the acquired image stacks. Biofilms produced by isolates Sm1 and Sm2, as visible in the 
images, demonstrated significant modification in biofilm morphology with increasing 
concentrations of EGCg, in contrast to COL treated biofilms (Figure 26). Although 
ATCC13637 strain was not structurally altered by EGCg or by COL, the red biofilm 
proportion increased with higher concentrations of these compounds. On the other 
hand, Sm2 structure was indeed modified, but the red biovolume proportion did not 
change. Quantitative results indicated reduction of total biovolume in all samples at 
highest concentrations (1×MIC), except for COL treated ATCC 13637.   
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Figure 26 Optical sections of 48-h-old S. maltophilia biofilms treated with EGCg and COL at 0.25×MIC, 0.5×MIC, 1×MIC. Biofilms were treated 
with formalin as killing control. Live bacteria are stained in green (Syto9), dead bacteria in red (propidium iodide [PI]) or yellow (overlapping regions). 
Experiments were performed in duplicate (image data: 1024 ×1024 pixel with a pixel-size of 0.284 µm; z-step-size: 2 µm). Length of size bar: 50 µm. 
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4. Discussion 
CF can be caused by a variety of different mutations in the CFTR gene, which usually 
disrupt exocrine function of multiple organ systems (Rowe et al., 1995). Dehydration of 
airway surfaces and impaired mucociliary transport are hallmarks of CF lung disease 
(Buzzetti et al., 2009; Goss and Burns, 2007). Therefore, under conditions of increased 
viscosity and osmolarity, adequate therapies to eliminate the presence of pathogens in 
these patients are problematic, normally leading to chronic lung colonisation and/or 
infection (Rowe et al., 2005). In addition, bacterial microorganisms are being 
increasingly described as a significant cause of morbidity and mortality amongst CF 
patients (de Vrankrijker et al., 2010). 
 
Recently, several centres worldwide have reported increased isolation of S. maltophilia 
from CF patients. Optimal clinical management relies on precise identification and 
susceptibility testing of this pathogen in the microbiology laboratory. Standardised and 
low-cost selective media have already been designed to isolate medically important 
pathogens such as P. aeruginosa and Burkholderia cepacia, but there is no 
institutionally recognised selective medium for S. maltophilia according to international 
guidelines (UK Cystic Fibrosis Trust, 2009; Hogardt et al., 2006) nor is such a medium 
yet commercially available. According to the British and German guidelines, detection of 
S. maltophilia and other atypical respiratory microorganisms should be conducted using 
Columbia blood agar and MacConkey agar. In the late 1980s, a selective medium was 
developed for the isolation of S. maltophilia (XMSM) from soil and rhizosphere (Juhnke 
and des Jardin, 1989). Subsequently, the formulation of VIA agar, which contained the 
selective agents vancomycin (5 mg/L), imipenem (32 mg/L), and amphotericin B 
(2.5 mg/L), was published (Kerr et al., 1996). Since S. maltophilia does not produced 
acid from mannitol, a mannitol/bromothymol indicator system was included in the 
formulation of this medium. A comparison between the selective properties of VIA and 
XMSM agar, by using faecal samples obtained from 32 children with haematological 
malignancy, revealed that VIA agar was clearly superior in selection of S. maltophilia in 
comparison to XMSM, since it allowed exclusive growth of S. maltophilia. Further, it was 
shown that isolation of S. maltophilia from 814 sputum samples obtained from CF 
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patients, using modified VIA agar cultures (amphotericin B concentration increase to 
4 mg/L), improved the detection of this pathogen. The authors noted that VIA agar 
supported the growth of 54.8 % more S. maltophilia isolates than bacitracin-chocolate 
agar.  
The slightly modified SMA presented in this study has no obvious advantages over VIA 
agar. Nonetheless, the improved detection of S. maltophilia by SMA confirms previous 
findings (Denton et al., 2000). Given the increasing prevalence of this emerging 
pathogen in the last decade, the use of a selective agar for isolation of S. maltophilia in 
sputum samples from CF patients is strongly advised. As shown in this work, both 
media, in addition to others, could identify the presence of S. maltophilia in 7.1% of all 
analysed samples, whilst SMA verified the presence of this pathogen in 11.0%, 
supporting the growth of 64.0% more than the conventional media. Although SMA 
should only be used for a period of three weeks post-preparation, due to the gradual 
degradation of imipenem activity, the easy formulation and fast processing of sputum 
makes it a potentially useful medium.  
There are only a few available studies regarding antimicrobial susceptibility of 
S. maltophilia samples from CF patients. The results from the current study indicated 
that tigecycline, trimethoprim-sulfamethoxazole, fosfomycin and levofloxacin exhibited 
remarkable in vitro activity against S. maltophilia, whereas ceftazidime, colistin and 
ticarcillin-clavulanate acid produced inferior results against this bacterium.  
A Spanish study has verified the effects of 41 antimicrobial agents against 76 
S. maltophilia isolates from CF patients admitted to the Ramón y Cajal Hospital CF Unit, 
Madrid (Cantón et al., 2003). The reported resistance rates for ceftazidime (70.0 %), 
ticarcillin-clavulanate acid (47.0 %) and trimethoprim-sulfamethoxazole (25.4 %) were 
higher than those presented in this study whilst, in comparison, moxifloxacin and 
levofloxacin exhibited lower resistance rates.  
An antimicrobial sensitivity investigation of 673 S. maltophilia samples from patients 
attending the CF Referral Center at Columbia University (New York City, USA) was 
carried out through broth microdilution assay (San Gabriel et al., 2004). Although MIC 
results for ticarcillin-clavulanate were similar to ours, the resistance rate for 
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trimethoprim-sulfamethoxazole (84.0 %) was, surprisingly, found to be higher than the 
one described in this study.  
On the subject of S. maltophilia susceptibility to levofloxacin, a Turkish group analysed 
genotype and susceptibility features of a small number of isolates (n=11) (Nazik et al., 
2007). The results demonstrated that 82.0 % of these isolates were susceptible to 
levofloxacin, revealing its efficacy against this pathogen. In addition, the authors also 
observed that all isolates were susceptible to trimethoprim-sulfamethoxazole.  
In Northern Ireland, S. maltophilia isolates from adult and paediatric CF patients (n=10) 
had their antibiotic susceptibility (MIC test strips) against levofloxacin characterised 
(McKnight et al., 2005). The data suggested, again, that levofloxacin showed excellent 
inhibitory activity against this bacterial agent.  
Antimicrobial effects of five drugs were tested against Gram-negative bacteria, among 
them S. maltophilia (n=51), obtained from CF patients attending either an American CF 
centre or the French hospital Jean Minjoz, Besançon (King et al., 2010). Levofloxacin 
was considered the most potent drug against all tested isolates. The aforementioned 
results were similar to our finding that 92.0 % of CF S. maltophilia isolates were 
susceptible to levofloxacin.  
Although, in the current investigation, colistin exhibited restricted activity against 
S. maltophilia isolated from CF patients, this data should be carefully interpreted. 
Colistin is administrated via inhalation to treat patients colonised and/or infected with 
Gram-negative bacteria, but interpretative in vitro criteria for susceptibility testing is 
assumed to translate into effective intravenous administration of this drug. Thus, further 
investigations are required to define the potential inhibitory effects of inhaled therapeutic 
agents. Unfortunately, breakpoints and interpretative criteria for moxifloxacin and colistin 
against S. maltophilia are yet to be established by the CLSI.         
 
Lipopolysaccharide (LPS) is an important pathogenic factor of Gram-negative bacteria. 
LPS is composed of three distinct regions: O-antigen, core and lipid A. The O-antigen 
and the core consist of polysaccharide chains, while lipid A is primarily composed of 
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fatty acid and phosphate substituents bonded to a central glucosamine dimer (Raetz and 
Whitfield, 2002). Since lipid A is able to induce cytokine release, it is, therefore, 
considered the major signalling component of LPS. In addition, previous evidence 
suggests that lipid A produced by P. aeruginosa could influence the pathogenesis of CF 
chronic lung disease (Ernst et al., 2003; Hajjar et al., 2002; Ernst et al., 1999). According 
to these studies, P. aeruginosa is able to synthesize a range of lipid A structures that 
could potentially promote bacterial survival or colonisation, since it can exhibit different 
inflammation-stimulating properties, or modify its lipid A structure to confer resistance 
against elements of host innate immunity.  
Previous studies demonstrated that LPS plays a role in the development and 
maintenance of various Gram-negative bacterial colonies (DeShazer et al., 1998; 
Goldberg et al., 1995). An early report addressing the temperature-dependent variation 
of S. maltophilia clinical isolates (n=38) revealed that their susceptibility to 
aminoglycoside antibiotics was significantly linked to changes in the LPS structures 
(Rahmati-Bahram et al., 1996). In the present study S. maltophilia samples from CF 
individuals produced a significantly higher amount of fatty acids in comparison to 
samples obtained from ICU patients and the environment. Additionally, the occurrence 
of distinguished groups of S. maltophilia categorised as “CF chronic colonist” and “CF 
non-chronic colonist” groups, suggests an adaptation mechanism of this microorganism 
to the CF airway. However, further investigations should be carried out to elucidate if 
antibiotic treatment against Gram-negative bacteria, during chronic infection, will 
influence fatty acid production. It is possible that S. maltophilia isolates from CF patients 
have a tendency to produce more fatty acids as a defense mechanism against long-term 
and repeated treatment with colistin (the mechanism of action relies on its ability to 
displace bacterial counter ions in LPS).  
 
MALDI-TOF MS is considered a method of phenotypic classification, which has been 
successfully applied in the past, specifically for species identification based on the 
protein composition of bacterial cells (Mellmann et al., 2008; Degand et al., 2008). This 
method is based on the detection of molecular masses of high abundant proteins in the 
regarded mass range, which produce species specific mass-spectral fingerprints 
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(Demirev et al., 1999). However, MALDI-TOF MS analyses of S. maltophilia mass 
spectra, from diverse sources, in order to unravel phylogenetic relationships and support 
genotype data, are still scarce.  
PCA is an analytical tool used to identify patterns in data and to express the results in a 
manner to emphasize their similarities and differences (Smith, 2002). Interestingly, the 
current results derived from PCA demonstrated that S. maltophilia CF isolates exhibited 
a particular MALDI-TOF spectra pattern from the other isolates (ICU and environmental), 
allowing them to cluster along the first principal component coordinate axis, therefore, 
suggesting a possible adaptation of this pathogen to the CF airway environment. In 
contrast, samples of this microorganism obtained from ICU individuals and the 
environment clustered in a mixed manner.  
Recently, a research group showed that mass spectra of nine environmental 
S. maltophilia isolates exhibited a particular fragment, approximately 6080Da in size 
(Vasileuskaya-Schulz et al., 2011). However, the present study could not confirm the 
presence of the referred peak in the environmental isolates and neither in the clinical 
isolates (CF and ICU). Taking this into consideration, it is still too early to be sure that 
the presence of 6080Da fragment is a species-specific marker. Therefore, further 
investigations are advisable. 
 
Natural genetic diversity could eventually explain most phenotypic differences amongst 
bacteria, e.g. geographic distribution, pathogenicity, host specificity, antibiotic resistance 
and virulence (Andrei and Zervos, 2006). Phylogenetic studies, at strain level, attempt to 
uncover convergence and divergence in evolution among samples of a 
species’ population. Therefore, typing methods often allow a better understanding of the 
ecology, as well as the dynamics of bacterial populations (Li et al., 2009). Through the 
years, typing methods have evolved from phenotypic to genotypic ones, due to the fact 
that traditional phenotypic markers are relatively unstable and do not provide satisfactory 
resolution power for strain discrimination (Li et al., 2009; Andrei and Zervos, 2006). 
Genotypic methods have the advantage of not being confounded by convergent 
evolution. Currently, a wide variety of complementary molecular genetic techniques are 
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available, that when used together, allow a comprehensive analysis of the species 
(Singh et al., 2006). In this study, heterogeneity of S. maltophilia was investigated using 
a set of isolates collected from CF and ICU patients, as well as from the environment. 
These strains were characterised and typed using the DL system and ERIC-PCR.   
Many typing methods revealed that S. maltophilia in CF patients and from other sources 
have high genetic diversity (Wu et al., 2011; Pompilio et al., 2011a; Marzuillo et al., 
2009; Nazik et al., 2007; Valdezate et al., 2001b; Denton et al., 1998).  
Denton et al. analysed 45 S. maltophilia isolates obtained from 41 paediatric CF patients 
(one isolate from each patient and fives isolates from a single patient). In this study they 
verified the presence of 41 ERIC-PCR types (Denton et al., 1998).  
A Spanish research group also examined the genetic features of S. maltophilia obtained 
from 25 CF patients (children and adults). This time, using a ribotyping technique and 
pulsed-field gel electrophoresis (PFGE). Among 76 isolates, DNA restriction enzyme 
digestion using XbaI identified 47 PFGE profiles (SID value of 0.97); whereas when 
digested with HindIII (SID value of 0.899) and BamHI (SID value of 0.915) 21 and 20 
ribotypes were detected, respectively (Valdezate et al., 2001b).  
Further, a study conducted in a Turkish hospital analysed the genotypes of 11 samples 
of S. maltophilia recovered from eight CF patients by using random amplified 
polymorphic DNA (RAPD)-PCR. The authors observed the presence of nine distinct 
RAPD types (Nazik et al., 2007).  
In Italy, molecular heterogenicity of S. maltophilia isolates collected from CF patients 
was also confirmed by the presence of 65 major PFGE profiles (Marzuillo et al., 2009). 
Another study of 98 S. maltophilia isolates demonstrated the presence of 36 out 47 and 
29 out 41 different PFGE profiles, among non-CF and CF isolates, respectively 
(Pompilio et al., 2011b).  
Recently, the DL rep-PCR typing method was used to study the clonal relatedness of 
S. maltophilia 47 clinical non-CF isolates. Molecular analysis through the DL system 
detected the presence of ten different clusters with 80.0 % similarity, while ten other 
samples did not cluster, suggesting unique strains (Wu et al., 2011).  
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Our results showed consistency with those presented, confirming the high degree of 
genetic heterogenicity among both clinical (CF and ICU) and environmental isolates 
supported and detected by the DL system and ERIC-PCR fingerprinting data. For the 
first time, a large number of S. maltophilia isolates, obtained from different sources, was 
evaluated at the molecular level by means of the DL system and ERIC-PCR. Based on 
the AR and W coefficient values, the current study could not establish congruence 
between those two typing methods. Given the fact that each technique is based on 
different attributes of genetic variation, it is not surprising that they do not entirely concur 
with one another. However, the results shown by one technique do not invalidate the 
data from the other. 
 
The adaptation of bacterial populations exposed to new or challenging environments, 
such as the CF airway, normally tend to result in spontaneous generation of mutator 
phenotypes (Giraud et al., 2001; Tenaillon et al., 1999). A mutable pathogen displays an 
increased spontaneous rate of mutation due to occurrence of defects in DNA 
proofreading and repair functions (Oliver, 2010; Oliver and Mena, 2010).  
Initially, to better understand the conditions required for bacterial 
colonisation/persistence, genetic diversity of S. maltophilia samples, consecutively 
isolated from chronically colonised CF patients, was examined. A high degree of 
diversity among these isolates was noted. This fits with results from previous studies 
(Valdezate et al., 2001b; Denton et al., 1998).  
A British study collected 45 S. maltophilia isolates during a period of 28 months from CF 
patients (one single isolate from each of 40 patients and five from a single patient). 
Through ERIC-PCR analysis, these clinical isolates were grouped into 41 different 
genotypes, of which 22 patients carried a unique type, four pairs of patients shared the 
same type and one patient was colonised with five different strains (Denton et al., 1998).  
Further, a Spanish prospective observational study conducted at the Hospital Ramón y 
Cajal (CF Unit) characterised the PFGE profiles of 76 S. maltophilia isolates from 25 CF 
patients. PFGE analysis revealed the presence of 47-well defined genomic profiles 
(Valdezate et al., 2001b).  
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Over the past decade, prevalence of mutator strains of P. aeruginosa in CF patients has 
been extensively investigated. For example, high prevalence of P. aeruginosa mutators 
in chronically colonised CF patients has been reported in Spain (37.0 %) and Denmark 
(54.0 %) as well as a wide range of other studies (Ferroni et al., 2009; Kenna et al., 
2007; Ciofu et al., 2005; Maciá et al., 2005; Oliver et al., 2000). Unfortunately, data 
regarding other CF pathogens is still limited (Turrientes et al., 2010; Román et al., 2004; 
Prunier et al., 2003).  
Mutation frequency of S. maltophilia isolates from the CF population was only partially 
addressed in a study conducted in Spain (Turrientes et al., 2010). According to the data 
presented, 16.7 % of the 48 clinical isolates obtained from 13 CF patients (three of them 
providing a single isolate) were considered strong hypermutators.  
In the current work, a high proportion of mutable S. maltophilia isolates (approximately 
31.0 %) were detected, suggesting their rapid adaptation to the CF lung environment. 
However, it was noted that genotypes shared by a number of patients tended, over time, 
to revert to their original nonmutator state. This can be justified by the fact that 
accumulation of deleterious mutations might decrease the overall fitness of the bacterial 
population (Taddei et al., 1997). 
Currently, antibiotic resistance is recognised as an increasing phenomenon and is a 
cause for concern, consequently resulting in limited choice of therapeutics, due to 
mutation playing a role in the evolution of bacterial resistance (Chopra et al., 2003). 
Different studies have shown that P. aeruginosa mutators were frequently more resistant 
to antibiotics in comparison to non mutator isolates (Henrichfreise et al., 2007; Ciofu et 
al., 2005; Oliver et al., 2000). In contrast, the present work showed no significant 
correlation between S. maltophilia mutators and increased antibiotic resistance. The 
reason for this discrepancy remains unclear, but a plausible explanation could be the 
scarcity of concrete guidelines for eradication of S. maltophilia (therapy duration and 
antimicrobial agents are not yet established). Therefore, selective pressure that would 
normally be higher if the pathogen was exposed to efficient therapeutic agents, is 
actually reduced, giving strains more chances to adapt (Döring et al., 2012). This 
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phenomenon has been observed in P. aeruginosa studies (Oliver, 2010; Hogardt and 
Heeseman, 2010; Ciofu et al., 2005).  
In general, chronic respiratory infection in CF patients is normally associated with 
progressive lung dysfunction and poor clinical status (Waters et al., 2013; Waters et al., 
2011; Razvi et al., 2009; Lambiase et al., 2006). Although suitable antibiotic treatment 
against S. maltophilia is not yet well established, current evidence indicates that 
eradication of bacterial pathogens improves the patient’s lung function (Dörig et al., 
2012; Tacetti et al., 2012). However, reliable diagnosis of S. maltophilia airway infection 
poses problems due to the difficulty in identifying this pathogen in CF patients who do 
not expectorate sputum, particularly young children (Ratjen et al., 2007; Kappler et al., 
2006). Thus, possible colonisation of the lower airway in these patients may not be 
properly recognised and consequently the correct immunological screening may not be 
carried out. This, together, could lead to incorrect patient clinical status interpretation. 
The importance of S. maltophilia in CF patients is hotly debated, since it is still unclear 
whether this pathogen is a real marker of disease severity or if it is causally related to 
disease progression (Waters et al., 2013; Waters et al., 2011). For this reason, there is a 
rising interest in exploring host-pathogen interactions that are responsible for 
progressive CF lung disease (Turrientes et al., 2010; Valdezate et al., 2001b; Denton et 
al., 1998).  
Previous studies have shown that serological tests are useful tools for monitoring 
therapeutic response and have also revealed that high levels of specific antibodies are 
associated with an increased risk for developing chronic infection (Dalbøge et al., 2011; 
Ratjen et al., 2007; Kappler et al., 2006). Since chronic exposure to a pathogen usually 
leads to a specific immune response, a simple and practical serological quantitative IFA 
to detect specific S. maltophilia antibody levels in CF patients was developed.  
S. maltophilia antibody titres correlated well with colonisation status. The data revealed 
that CF patients with “chronic S. maltophilia” colonisation status exhibited a significantly 
higher antibody titre in comparison to all other characterised groups in this study 
(healthy subjects (P <0.0001), “CF never S. maltophilia/P. aeruginosa” (P=0.0002), “CF 
intermittent S. maltophilia” (P=0.0315)).  
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Similar findings were also observed in Danish and Canadian cohorts. The amount of 
precipitating S. maltophilia antibodies was measured by crossed 
immunoelectrophoresis. The results revealed that chronically colonised patients (n=21) 
attending the Copenhagen CF centre had antibody titres, that increased during a period 
of two years (Dalbøge et al., 2011). Likewise, research conducted at the Hospital for 
Sick Children and St. Michael’s Hospital (Toronto, Canada), using ELISA, showed that 
S. maltophilia antibody titres against whole cell (P=0.0004) and flagellin (P<0.0001) 
were higher in CF “chronic” than CF “intermittent” or “never S. maltophilia” groups 
(Waters et al., 2011) 
Identification and differentiation of serological responses to P. aeruginosa and 
S. maltophilia, expressed by the majority of CF “S. maltophilia chronic” patients, 
particularly, ruling out cross-reactivity, was one of the biggest technical obstacles in 
developing an IFA. In order to reduce the presence of any residual antibodies in the sera 
from the CF patient groups, non-specific antibody absorption using P.  aeruginosa whole 
cells was conducted with all samples. S. maltophilia whole-cells were used as the target 
antigen for the IFA. The reason for choosing S. maltophilia whole-cells was based on the 
fact that some epitopes are unsuitable because they are buried within the outer 
membrane and consequently may not be available on the bacterial surface (Bakri et al., 
2002). Thus, antibodies capable of binding to intact bacteria are more likely to provide a 
protective immune response (Bakri et al., 2002).   
Interestingly, ROC data allowed us to establish a cut-off value of >1:120 titre with a high 
degree of confidence based on satisfactory specificity (81.8 %) and sensitivity (78.5 %). 
Since specificity and sensitivity are not determined by the prevalence of S. maltophilia 
colonisation in the evaluated CF population, the NPV value was measured. A NPV value 
of 84.7 % indicated that only 15.3 % of the CF patients produced false positive results 
when tested for S. maltophilia antibodies. Therefore, from a clinical standpoint, 
assessment of both culture and serology results might represent a unique window for 
intervention to eradicate the organism before the onset of chronic infection, and also to 
monitor CF patients’ S. maltophilia colonisation status.    
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CF patients are generally susceptible to bacterial respiratory infections due to impaired 
mucociliary clearance competence (O’Sullivan and Freedman, 2009). Furthermore, 
treatment of these bacterial infections play a major role in assuring lung function by 
reducing the impact of infection, inflammation, and reduces the incidence of subsequent 
lung injury (Döring et al., 2012). Notably, in vitro evidence showed that epigallocatechin-
3-gallate (EGCg), an abundant polyphenol found in green tea (Camellia sinesis), is an 
effective antimicrobial agent against a range of Gram-positive and Gram-negative 
bacterial and fungal pathogens (Steinmann et al., 2013; Xu et al., 2011; Gordon and 
Wareham, 2010; Osterburg et al., 2009; Hirasawa and Takada, 2004).    
EGCg in vitro antimicrobial activity was evaluated using 60 S. maltophilia isolates 
obtained from different CF patients. Interestingly, the MIC (MIC50/90= 256 mg/L) and 
time-killing data were similar to those described by Gordon and Wareham with a cohort 
of 40 clinical isolates from non-CF patients (Gordon and Wareham, 2010). In addition, in 
vivo antibacterial efficacy of EGCg was tested by performing intratracheal instillation 
infection in wild type and CF mice. The results revealed that bacterial counts in the lungs 
of mice treated with EGCg were significantly reduced, indicating a bactericidal effect and 
possible suppression of bacterial dissemination. On the other hand COL, solely 
administrated, was not as effective as EGCg, a fact that has been previously observed 
in a different in vivo model when infected with P. aeruginosa (Herrmann et al., 2010).  
MIC and MBC per se do not provide suitable evidence regarding the efficacy of 
antimicrobial drugs against bacteria that live in biofilm mode because these results are 
obtained from assays using planktonic cells. It is important to remember that slow 
growth rate, low metabolic activity and production of a protective matrix of extracellular 
polymeric substances are biofilm-specific features that will contribute to pathogen 
resistance and poor host response (Costerton et al., 1999). Thus, biofilm formation is a 
survival strategy for bacteria.    
In the current study, a high percentage of S. maltophilia isolates from CF patients 
(90.0 %) were able to produce biofilm on polystyrene surfaces.  An Italian research 
group has described similar data and they also observed that S. maltophilia’s biofilm 
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formation ability was influenced by different environmental conditions, such as 
temperature, oxygen availability and pH (Di Bonaventura et al., 2007). 
Since the biofilm mode of growth is an effective defence mechanism developed by the 
bacteria to survive in the challenging environment of the CF airway, the impact of COL 
and EGCg on biofilm formation and on various maturation stages of the biofilm was 
assessed. It was verified that COL and EGCg at subinhibitory concentrations 
considerably reduced biofilm formation as well as cell viability of S. maltophilia samples 
tested, with the strongest effect observed at the 0.5×MIC concentration for both 
compounds. Previous reports have demonstrated that quinolones also display anti-
biofilm properties against S. maltophilia at sub-MIC concentrations (Pompilio et al., 
2010a; Di Bonaventura et al., 2004). For example, ciprofloxacin, grepafloxacin, and 
norfloxacin significantly reduced not only biomass, but also the viability of S. maltophilia 
biofilm at concentration of 0.25×MIC (Di Bonaventura et al., 2004). Furthermore, the 
same research group also noticed that subinhibitory concentration of moxifloxacin 
induced a significant reduction in adhesion and biofilm formation of two S. maltophilia 
isolates from CF patients (Pompilio et al., 2010a).        
The present study verified, for the first time, whether bactericidal and/or subinhibitory 
concentrations of COL and EGCg were able to damage young and mature biofilms. At 
various concentrations, in vitro data showed that COL and EGCg reduced 24-h-old and 
7-day-old biofilm biovolume. In addition, when biofilm susceptibility testing was assessed 
by CLSM, strong effects were noticed after EGCg treatment both with regard to 
morphology and viability. Conversely, COL only decreased the total biovolume of the 
clinical isolates, as previously evidenced by crystal violet staining experiments.  
Although anti-biofilm therapies against medically relevant bacterial pathogens have 
accrued a significant level of interest, currently there are, as yet, no clearly established 
treatments to specifically target biofilms. Thus, novel therapeutic solutions for preventing 
and/or controlling biofilm-associated bacterial infections are urgently needed (Høiby, 
2002).  
Green tea is not only attractive as a foodstuff, but is also recognised as a millenary 
substance used in traditional medicine in most Asian countries; and interest in its 
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medicinal properties are rising in the Western world (Benelli et al., 2002). Diverse 
epidemiological investigations have shown that green tea positively affects the health of 
patients suffering from cancer, cardiovascular and neurological diseases (Zaveri, 2006; 
Benelli et al., 2002). It also exhibits antimicrobial activity. Several epidemiological 
studies verified that sub-MIC concentrations of EGCg were effective against biofilms 
produced by other microbial agents, such as Streptococcus mutans, Staphylococcus 
aureus, and Candida albicans (Steinmann et al., 2013; Evensen and Braun, 2009; 
Sudano Roccaro et al., 2004). Further analyses demonstrated that EGCg in normal 
human lung cells, even at high concentrations, shows a low toxicity, suggesting it as a 
potential candidate for development of novel therapies to treat respiratory infections in 
CF patients (Wu et al., 2012; Isbrucker et al., 2006a; Isbrucker et al., 2006b). One 
pharmacokinetic challenge to the therapeutic utilisation of EGCg is the instability of the 
EGCg molecule (1.8 and 4.9 h for free EGCG and between 1.9 and 4.6 h for total EGCG 
(Ulmann et al., 2003)); but nebulisation emerges as a promising alternative strategy for 
improving mucociliary impairment and respiratory function among CF patients 
(O'Connell et al., 2011). For example, a clinical study performed with elderly disabled 
patients demonstrated that inhalation of a green tea extract was able to eradicate 
Methicillin-resistant S. aureus from the upper respiratory tract (Yamada et al., 2006).  
The mechanism of action involved in the activity of EGCg against bacterial growth 
remains unclear. It has been proposed that EGCg is an efficient inhibitor of the 
S. maltophilia dihydrofolate reductase enzyme, which consequently leads to disruption 
of DNA synthesis (Navarro-Martínez et al., 2005). Contrarily, other studies suggested 
that catechins might play a crucial role in damaging bacterial membranes or cell 
membranes of various pathogens (Arakawa et al., 2004; Hirasawa and Takada, 2004). 
Recently, atomic force microscopy showed evidence that important morphological 
changes to Gram-negative bacterial cell surfaces induced by EGCg were highly 
depended on the release of hydrogen peroxide (H2O2) (Cui et al., 2012). One molecule 
of EGCg, in phosphate buffer at neutral pH, can produce up to two molecules of H2O2 
(Arakawa et al., 2004). Hydroxyl radicals derived from H2O2 are recognised for their 
ability to damage polyunsaturated fatty acids in membranes and initiate lipid 
peroxidation, altering the membrane properties, such as fluidity (Cabiscol et al., 2002). 
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Based on these facts, it was demonstrated that treatment of E. coli 0157:H7 with sub-
MIC of EGCg led to temporary pore-like lesions in the cell wall and degradation of the 
outer membrane (Cui et al., 2012).  
Biofilms usually have a high level of cellular activity at the surface, whereas regions 
towards the core are considered to have low activity and slow growth or no detectable 
growth (Yamada et al., 2006). The hypothesis is that EGCg’s anti-biofilm effects are not 
related to metabolic activity, but instead are related to its ability to bind and damage 
bacterial membranes (Cui et al., 2012).   
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5. Conclusions and future research 
This dissertation has given an account of, and the reason for, the emergence of 
S. maltophilia as a progressive cause of morbidity and mortality in CF patients. The 
purpose of the current study was to better understand the role of this pathogen in the 
CF-lung environment.    
The following conclusions can be drawn from the present study:  
 Implementation of a selective medium for S. maltophilia improved the rate of 
identification for this pathogen in comparison to conventional media.  
 Findings of characterisation experiments showed that S. maltophilia isolates had 
a high degree of genetic heterogeneity among clinical (CF and ICU) and 
environmental isolates, and also revealed that CF S. maltophilia samples 
produced a significantly higher amount of fatty acids in comparison to others cited  
above.  
 The presence of S. maltophilia mutator strains recovered from chronically 
colonised CF patients and their lack of increasing resistance in comparison to 
non-mutator isolates serve as reliable markers of this pathogen’s biological 
fitness for long-term persistence in the CF-lung.  
 Patients chronically colonised by S. maltophilia exhibited a specific immune 
response and displayed significantly higher antibody titres in comparison to other 
individual groups.  
 EGCg, the main component of green tea, exhibited antimicrobial properties 
against S. maltophilia acute pulmonary infection and in vitro biofilm.  
The evidence from this study suggests that S. maltophilia is a versatile bacterium. Its 
multi-drug resistance coupled with its biofilm-producing characteristic, raises strong 
concerns in the medical community. Consequently, development of measures to control 
infection in the CF population caused by this pathogen is urgently required.  
However, a number of limitations should be considered. Although it is considered 
representative, the current number of ICU and environmental samples included was 
relatively small. An issue that was not addressed was whether naturally hypermutable 
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strains have an associated biological benefit or cost when colonising a host. Finally, the 
study did not evaluate the use of EGCg as either a prophylactic or therapeutic treatment.  
Further experimental investigation should determine the relevance of increased 
S. maltophilia antibody titres over time; the significance of seroconversion in childhood; 
and whether antibody titre is reduced after specific therapy against S. maltophilia. In 
addition, the experiments described in this work demonstrated that EGCg is detrimental 
to S. maltophilia biofilm integrity in vitro. It would be interesting to assess the role of 
EGCg in in vivo CF models during S. maltophilia chronic infection.  
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6 Summary 
Cystic fibrosis (CF) is an autosomal recessive disorder that affects mainly the Caucasian 
population. CF patients frequently suffer from chronic bacterial airway infections, which 
are progressively described as an important cause of high morbidity and mortality rates 
among these individuals. In this scenario, Stenotrophomonas maltophilia, an 
environmental Gram-negative rod, has been lately reported as a global emerging 
bacterium by CF centres worldwide. At the moment, it is still unclear whether 
S. maltophilia is causally related to disease progression or if this pathogen is real a 
marker of the CF disease’s severity. In the present study, the relevance and importance 
of S. maltophilia was investigated. The major findings were:  
 The use of selective medium for S. maltophilia supported the growth of the 
S. maltophilia 64.0 % more than the conventional media. It was also verified that 
tigecycline, trimethoprim-sulfamethoxazole, fosfomycin and levofloxacin exhibited 
good in vitro activity against S. maltophilia, while ceftazidime, colistin and 
ticarcillin-clavulanate acid had low activity against this bacterium. 
 Different fingerprinting methods, Enterobacterial Repetitive Intergenic Consensus 
- polymerase chain reaction (ERIC-PCR) and semi-automated Repetitive 
Sequence-Based-polymerase chain reaction (rep-PCR) DiversiLab® system, 
demonstrated high degree of genetic heterogeneity among both clinical (CF and 
ICU) and environmental S. maltophilia isolates. Further, gas chromatography data 
revealed that S. maltophilia samples from CF individuals produced a significant 
higher amount of fatty acids in comparison to samples obtained from ICU patients 
and environment. Interestingly, principal component analysis based on Matrix-
Assisted Laser Desorption Ionisation-Time of Flight Mass Spectrometry (MALDI-
TOF MS) spectra revealed that S. maltophilia isolates from CF patients are 
clustered together in a separated group, whereas ICU and environmental 
samples grouped in a mixed manner indicating adaptation or strains that show 
different disease specific characteristics. 
 Development of a quantitative immunofluorescence assay (IFA) showed that CF 
patients with “chronic S. maltophilia” had a specific immune response and had a 
significantly higher S. maltophilia antibody levels compared with healthy 
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individuals, CF patients with “intermittent” or “never S. maltophilia/Pseudomonas 
aeruginosa”. A discriminant cut-off value of >1:120 titre was established to 
differentiate “CF chronic S. maltophilia” from the other groups. This assay could 
be useful to screen S. maltophilia colonisation status of CF patients at an early 
stage of disease and it may also assist on the decision of whether initiation of 
targeted therapy should be made or not. 
 
 S. maltophilia bacterial population recovered from chronically colonised CF 
patients was highly diverse and revealed the presence of mutator strains. 
However, these mutator isolates did not show increased resistance to antibiotics 
in comparison to non-mutator isolates. This kind of adaptation mechanism cost 
fitness. These results suggest that S. maltophilia attempts to sustain its biological 
fitness as mechanism for long-term persistence in the CF lung. 
 
 EGCg, a natural compound from green tea, displayed in vivo antimicrobial effects 
against S. maltophilia acute pulmonary infection and in vitro anti-biofilms 
properties against S. maltophilia isolates recovered from CF individuals. This 
compound might be a promising novel therapeutic inhaling agent against 
S. maltophilia colonisation and infection in patients with CF. 
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